Colorectal Cancer Screening Demonstration Program, 29747-29759 [05-10296]
Download as PDF
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Request for Applications (RFA) AA006]
Increasing Access to HIV Counseling
and Testing (VCT) and Enhancing HIV/
AIDS Communications, Prevention,
and Care in Botswana, Lesotho, South
Africa, Swaziland, and Cote d’Ivoire—
Amendment
A notice announcing the availability
of fiscal year (FY) 2005 funds for
Increasing Access to HIV Counseling
and Testing (VCT) and Enhancing HIV/
AIDS Communications, Prevention, and
Care in Botswana, Lesotho, South
Africa, Swaziland, and Cote d’Ivoire
was published in the Federal Register
on Tuesday, May 3, 2005, Volume 70,
Number 84, pages 22870–22875. The
notice is amended as follows:
Replace the current language on page
22873, columns two and three,
regarding Prostitution and Related
Activities with the following:
• Prostitution and Related Activities.
The U.S. Government is opposed to
prostitution and related activities,
which are inherently harmful and
dehumanizing, and contribute to the
phenomenon of trafficking in persons.
Any entity that receives, directly or
indirectly, U.S. Government funds in
connection with this document
(‘‘recipient’’) cannot use such U.S.
Government funds to promote or
advocate the legalization or practice of
prostitution or sex trafficking. Nothing
in the preceding sentence shall be
construed to preclude the provision to
individuals of palliative care, treatment,
or post-exposure pharmaceutical
prophylaxis, and necessary
pharmaceuticals and commodities,
including test kits, condoms, and, when
proven effective, microbicides. A
recipient that is otherwise eligible to
receive funds in connection with this
document to prevent, treat, or monitor
HIV/AIDS shall not be required to
endorse or utilize a multisectoral
approach to combating HIV/AIDS, or to
endorse, utilize, or participate in a
prevention method or treatment
program to which the recipient has a
religious or moral objection. Any
information provided by recipients
about the use of condoms as part of
projects or activities that are funded in
connection with this document shall be
medically accurate and shall include the
public health benefits and failure rates
of such use.
In addition, any recipient must have
a policy explicitly opposing prostitution
VerDate jul<14>2003
18:00 May 23, 2005
Jkt 205001
and sex trafficking. The preceding
sentence shall not apply to any ‘‘exempt
organizations’’ (defined as the Global
Fund to Fight AIDS, Tuberculosis and
Malaria, the World Health Organization,
the International AIDS Vaccine
Initiative or to any United Nations
agency).
The following definition applies for
purposes of this clause:
• Sex trafficking means the
recruitment, harboring, transportation,
provision, or obtaining of a person for
the purpose of a commercial sex act. 22
U.S.C. 7102(9).
All recipients must insert provisions
implementing the applicable parts of
this section, ‘‘Prostitution and Related
Activities,’’ in all sub-agreements under
this award. These provisions must be
express terms and conditions of the subagreement, must acknowledge that
compliance with this section,
‘‘Prostitution and Related Activities,’’ is
a prerequisite to receipt and
expenditure of U.S. government funds
in connection with this document, and
must acknowledge that any violation of
the provisions shall be grounds for
unilateral termination of the agreement
prior to the end of its term. Recipients
must agree that HHS may, at any
reasonable time, inspect the documents
and materials maintained or prepared
by the recipient in the usual course of
its operations that relate to the
organization’s compliance with this
section, ‘‘Prostitution and Related
Activities.’’
All prime recipients receiving U.S.
Government funds (‘‘prime recipients’’)
in connection with this document must
certify compliance prior to actual
receipt of such funds in a written
statement referencing this document
(e.g., ‘‘[Prime recipient’s name] certifies
compliance with the section,
‘‘Prostitution and Related Activities.’’’)
addressed to the agency’s grants officer.
Such certifications by prime recipients
are prerequisites to the payment of any
U.S. Government funds in connection
with this document.
Recipients’ compliance with this
section, ‘‘Prostitution and Related
Activities,’’ is an express term and
condition of receiving U.S. Government
funds in connection with this
document, and any violation of it shall
be grounds for unilateral termination by
HHS of the agreement with HHS in
connection with this document prior to
the end of its term. The recipient shall
refund to HHS the entire amount
furnished in connection with this
document in the event it is determined
by HHS that the recipient has not
complied with this section,
‘‘Prostitution and Related Activities.’’
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
29747
Dated: May 18, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–10293 Filed 5–23–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Colorectal Cancer Screening
Demonstration Program
Announcement Type: New.
Funding Opportunity Number: RFA
AA030.
Catalog of Federal Domestic
Assistance Number: 93.283.
Key Dates: Letter of Intent (LOI)
Deadline: June 8, 2005.
Application Deadline: July 8, 2005.
Executive Summary: Colorectal
Cancer (CRC) is the second leading
cause of cancer-related deaths in the
United States, following lung cancer (1American Cancer Society 2005, see
Attachment D). Strong scientific
evidence indicates that regular
screening is effective in reducing CRC
incidence and mortality (2—Mandel
1993, 3—Mandel 2000, 4—Selby 1992,
5—Kronburg 1996, 6—Hardcastle 1996,
see Attachment D).
Screening rates for CRC are currently
lower than other cancer screening
services (7—Seeff 2004). CRC screening
is already occurring in some
communities, either in an organized or
an opportunistic setting. Some
communities are planning to begin
screening, but are still building their
infrastructure and/or resources.
The Centers for Disease Control and
Prevention (CDC) announce the
availability of funds in fiscal year (FY)
2005 for three to five cooperative
agreements to implement demonstration
programs designed to increase
population-based CRC screening among
persons 50 years and older in a
geographically defined area, with
screening efforts focused on persons 50
years and older with low incomes and
inadequate or no health insurance
coverage for CRC screening (priority
population). Applicants will need to
define the geographic area that their
program will cover. Applicants will be
asked to describe their current CRC
screening efforts and to define what
they need to increase CRC screening
rates in these two populations: (1) The
larger geographically-defined
population; and (2) the priority subpopulation within that geographically-
E:\FR\FM\24MYN1.SGM
24MYN1
29748
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
defined area. CDC will choose among
applicants based on specific evaluation
criteria described in this RFA. These
will be three year demonstration
programs, pending availability of funds.
I. Funding Opportunity Description
Authority: This program is authorized
under section 317(k)(2) of the Public
Health Service Act, [42 U.S.C. section
247b(k)(2)], as amended.
Background: Colorectal Cancer (CRC)
is the second leading cause of cancerrelated deaths in the United States,
following lung cancer (1). Screening for
CRC works both through the
identification and removal of
precancerous polyps, and the early
detection of cancers. Strong scientific
evidence indicates that regular
screening is effective in reducing CRC
incidence and mortality (2–6).
Randomized controlled trials have
demonstrated a reduction in CRC
incidence and mortality with annual
and biennial fecal occult blood testing
(FOBT) and case-control studies have
shown a reduction in CRC mortality
associated with the use of
sigmoidoscopy. Indirect evidence
supports the effectiveness of
colonoscopy and double-contrast
barium enema (DCBE) for use as CRC
screening tests.
Based on scientific evidence, national
guidelines have been developed
recommending regular CRC screening
for average-risk persons with one or
more of the following options: FOBT,
sigmoidoscopy, FOBT and flexible
sigmoidoscopy in combination;
colonoscopy, and/or DCBE. The U.S.
Preventive Services Task Force
(USPSTF) strongly recommends that
clinicians screen men and women 50
years of age or older for CRC and give
an ‘‘A’’ recommendation to regular CRC
screening with one of the above listed
testing options. Fecal Immunochemical
Testing (FIT) is considered an
acceptable alternative to FOBT. These
tests vary in their costs, availability, and
associated risks, and current evidence
does not clearly demonstrate which of
these tests is most effective.
National survey data show that only
approximately half of eligible adults
have been screened for CRC according
to recommended guidelines. A number
of factors are likely contributing to low
screening rates including: (1) Lack of
knowledge by the public that CRC is
common and screening is effective; (2)
lack of physician recommendations to
get regular screening; (3) lack of a
regular health care provider; (4) patient
embarrassment, fear of cancer, poor
reimbursement; (5) limited insurance
coverage for CRC screening or lack of
VerDate jul<14>2003
18:10 May 23, 2005
Jkt 205001
insurance; and (6) lack of organized
systems where screening and follow-up
may be conducted. Other barriers may
exist which are recognized in
community settings but not documented
in published literature.
Purpose: The purpose of this program
is to establish demonstration programs
to increase population-based CRC
screening among persons 50 years and
older in a geographically defined area,
and to focus screening efforts on
persons with low incomes and
inadequate or no health insurance
coverage for CRC screening. This
program addresses the ‘‘Healthy People
2010’’ focus area Cancer, specifically to
increase the proportion of adults who
receive a colorectal screening
examination. https://
www.healthypeople.gov/Document/pdf/
Volume1/03Cancer.pdf.
Measurable outcomes of the program
will be: To increase the CRC screening
rate among persons 50 years and older
in a geographically defined area overall
(as defined by the applicant), and
among persons 50 years and older
within that geographically-defined area
with low incomes and inadequate or no
health insurance coverage for CRC
screening in particular. The CRC
screening demonstration programs will
need to set their own goal for a
projected increase in the number or
percentage of CRC screens. Screening
rates using one or a combination of the
following tests will be measured: FOBT
or FIT annually, sigmoidoscopy every 5
years, FOBT and flexible sigmoidoscopy
in combination; colonoscopy every 10
years, and/or DCBE every 5 years. No
CDC Government Performance and
Results Act (GPRA) measure currently
addresses CRC screening.
This announcement is only for nonresearch activities supported by CDC/
ATSDR. If research is proposed, the
application will not be reviewed. For
the definition of research, please see the
CDC Web site at the following Internet
address: https://www.cdc.gov/od/ads/
opspoll1.htm.
Special Guidance for Technical
Assistance: Technical assistance will be
available for potential applicants on two
one-hour conference calls, one morning
and one evening, scheduled one week
after the LOIs are due. Please call 1–
888–455–5920 and enter conference
passcode 50260 at 3 p.m. EST on
Wednesday June 22, 2005 or 1–888–
455–5920 and enter conference
passcode 32070 at 9 a.m. on Thursday
June 23, 2005.
Activities: Cooperative agreement
applicants do not have to request
funding for each of the program
components described below. Awardee
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
activities for this program may include,
but are not limited to the activities
listed below:
1. Program Management
a. Establish specific, measurable, and
realistic short-term (one year) and longterm (three year) objectives consistent
with the purpose of this program
announcement for the accomplishment
of the program activities, including the
establishment of realistic screening
goals.
b. Recruit and develop staff to
maintain the program.
c. Develop a fiscal system that tracks
and monitors program expenditures and
ensures the accurate and timely
reimbursement of services provided by
the program.
d. Develop accurate budget requests
that correspond with program
workplans and prepare/submit required
reports on a timely basis.
Performance will be measured by the
extent to which the program (1)
establishes specific, measurable and
realistic objectives (including realistic
screening goals); (2) hires/identifies and
maintains qualified staff; (3) spends
funding efficiently and effectively; and
(4) effectively addresses problems as
they arise.
2. Provision of Screening and Diagnostic
Follow-up Services
a. Provide CRC screening and
diagnostic follow-up services for
persons 50 years and older with low
incomes and inadequate or no health
insurance coverage for CRC screening in
organized, CRC screening demonstration
programs. A more specific priority
population can be proposed if this can
be justified. The level of poverty of the
priority population will be defined by
the applicant (typically at or below 250
percent or 200 percent of the Federal
poverty level). In the absence of data
suggesting which screening test is most
effective, grantees will be given
flexibility in the selection of screening
tests with two important caveats: (1)
Grantees can only offer screening tests
for which test availability has been
assessed and capacity has been
demonstrated; and (2) grantees can only
offer screening tests recommended by
the U.S. Preventive Services Task Force
(USPSTF). Since FIT is considered an
acceptable alternative to FOBT, it will
be a reimbursable service within these
programs as an alternative to FOBT, if
the program desires. Acceptable tests
include:
• Guaiac-based FOBT annually (athome only).
E:\FR\FM\24MYN1.SGM
24MYN1
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
• Immunochemical FOBT (FIT
annually will be considered as an
alternative to FOBT).
• Flexible sigmoidoscopy every five
years.
• Double-contrast barium enema
every five years.
• Colonoscopy every ten years.
b. Implement a program design that
offers a single screening test or multiple
screening tests. The selection of
screening tests offered in the
demonstration program may change
over the three year period pending prior
approval and availability of funds, if a
program finds that a test is not in
demand among the priority populations
or if a newer test is added to USPSTF
guidelines during the funding period.
c. Demonstrate readiness to begin
offering screening services within six
months of award. Elements which will
be evaluated to determine readiness
include: (1) The identification of
providers to perform screening and
follow-up service, and to provide care in
the event of unanticipated
complications; (2) a plan to recruit
persons for screening from the larger
geographically-defined population and
the priority population; (3) a final set of
data quality indicators, defined in
collaboration with CDC, to be used by
the grantees and CDC in assessing the
quality of the services provided within
the demonstration programs; (4) a final
data collection and tracking system; and
(5) a plan and funding sources to
provide treatment for those persons in
whom cancers are identified. CDC will
make a site visit within six months of
award to assess readiness and approve
commencement of screening activities.
Performance will be measured by the
extent to which the applicant (1)
increases the number of people screened
within both the defined geographic area
and the priority population; and (2)
meets the projected number of screens
or the proportional increases in
screening as set by the program.
3. Public Education and Outreach
a. Develop and carry out strategies to
increase awareness about CRC screening
including building on existing public
education efforts at the local, state and
national level that are consistent with
evidence-based interventions
recommended in the Community Guide
to Preventive Services. Programs may
utilize campaign materials from CDC’s
Screen for Life: National Colorectal
Cancer Action Campaign ‘‘Screen for
Life,’’ which can be tagged for
individual program use.
b. Develop and implement an
outreach workplan that includes a mix
of broad-based activities and one-on-one
VerDate jul<14>2003
18:04 May 23, 2005
Jkt 205001
outreach, using methods known to be
effective in reaching priority
populations for CRC screening.
Performance will be measured by the
extent to which (1) the program can
demonstrate the appropriate and
effective use of public education and
outreach strategies and (2) CRC
screening rates are increasing in both
the geographically defined area and the
priority population.
4. Quality Assurance/Professional
Development
a. Establish standards, systems,
policies and procedures to maintain
quality services, including tracking and
follow-up systems to assure the
provision of appropriate and timely
follow-up of all abnormal screening
results and/or diagnoses of cancer.
b. Change/develop systems or policies
to better support high quality CRC
screening and related care based on an
assessment and prioritization of needs.
c. Identify a plan and funding sources
to provide treatment for anyone
diagnosed with cancer in the
demonstration program.
d. Identify a plan to provide treatment
for anyone who incurs an unanticipated
medical complication from services
offered within the demonstration
program.
e. Convene a medical advisory board
to provide oversight of the quality of
services being delivered throughout the
three year funding period. CDC will be
providing medical and clinical technical
assistance to individual programs, and
will convene a federal-level CRC
Demonstration Screening Program
Workgroup to assist in the development
of overall program policies and
procedures.
f. Develop or enhance initiatives to
educate and train health professionals
in the detection and control of CRC,
including quality of screening and
follow-up care.
Performance will be measured by the
extent to which the program (1)
establishes and uses quality indicators,
systems and policies/procedures to
monitor and measure the quality of
services provided, including a medical
advisory board and; (2) successfully
conducts appropriate and timely followup of abnormal test results and provides
referrals to treatment, staging, clinical
evaluation of symptoms or treatment of
unanticipated complications.
5. Partnership Development and
Maintenance
a. Maintain a relationship with the
CDC-funded comprehensive cancer
control (CCC) implementation
program(s) (and their coalitions) within
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
29749
the applicant’s state(s) to ensure
coordination and integration of program
activities with related CCC activities,
including alignment of program
activities with CCC plans.
b. Develop and maintain collaborative
partnerships with a diverse set of
entities (such as patients, cancer
survivors, community-based
organizations, groups that serve or
represent priority populations, human
service agencies, public health agencies,
voluntary agencies, public and private
local businesses and employers,
nonprofit agencies and institutions,
medical providers and health care
system representatives) to enhance the
design and implementation of the
program.
Performance will be measured by the
extent to which the program: (1)
Demonstrates a strong association with
the CCC program/coalition; (2) has
included any appropriate and diverse
additional partners in program
planning; (3) has obtained and can show
commitment from participating
partners; (4) has documented the roles
that partners and CCC Coalition
members will play; (5) has obtained
representation from the priority
populations and has clearly defined a
role for representatives from priority
populations in program design and
implementation. A listing of all CDCfunded CCC programs (implementation
level) is provided with this RFA as
Attachment A.
6. Data Collection and Tracking
a. Adapt current data collection
system and develop data reports to be
submitted to CDC related to CRC
screening and other clinical and
program activities that are part of this
demonstration project. Please see
Attachment B, Tables B–1 and B–2.
These tables represent draft data items
that CDC is proposing should be
collected by the grantees to assess the
quality and appropriateness of the
services provided within the
demonstration programs. Grantees will
be asked to propose data items they feel
would be most effective in showing an
increase in screening in both the
geographically-defined population and
the priority population. Grantees will
also be asked to propose the best
manner in which to collect these data.
Using the information proposed by
grantees and the draft tables in
Attachment B, grantees will work with
CDC to finalize an agreed upon set of
data items, similar to those in the draft
tables. Grantees must assure that the
data collected at the individual patientlevel will be sufficient for grantees to be
able to track the quality and timeliness
E:\FR\FM\24MYN1.ROB
24MYN1
29750
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
of care (including treatment and routine
recall) and will adhere to current
standards related to data-sharing, data
security and patient confidentiality. All
submitted data must be de-identified.
Some applicants may only request
funds for components of this program
other than screening service delivery.
Even if an applicant chooses to use nonCDC funding sources to fund their
screening service delivery component,
all grantees will be required to submit
data on the CRC screening and
diagnostic services delivered as part of
this demonstration project.
b. For grantees that request CDC funds
for the screening service delivery
component of this program: Collect
individual patient-level data to capture
clinical services and outcomes and
submit aggregate data to CDC.
Aggregated data reports will include the
proportion of persons within the
geographic area defined by the grantee
receiving the specific clinical services
offered within this program, by each of
the demographic variables (for example,
a report may include the proportion of
persons within the defined geographic
area receiving FOBT by age, gender,
race, ethnicity, and income level).
Develop data quality indicators, in
conjunction with CDC, to be used by the
grantees and CDC in assessing the
quality of the services provided within
the demonstration programs. Grantees
may be asked by CDC to submit
individualized data if submitted
aggregate data do not meet data quality
indicator standards. The data included
in Attachment B, Draft Table B–1,
‘‘Patient-Related Data Elements,’’
variable domains 1–7, represent the type
of information submitted by the
program to CDC that CDC will use to
monitor the quality of services delivered
(1-unique identifiers, 2-demographics,
3-screening history, 4-screening
information, 5-diagnostic procedures
provided, 6-cancer/polyp diagnosed, 7treatment). Final data elements used to
obtain this information will be agreed
upon by CDC and the grantees. During
the three year program period, CDC may
begin requiring all data submissions
from grantees that receive CDC funds for
screening services to be individual
patient-level data, pending approval
from the Office of Management and
Budget (OMB).
c. For grantees that do NOT request
CDC funds for the screening service
delivery component of this program:
collect individual patient-level data but
submit aggregate patient-level data to
CDC. Develop data quality indicators, in
conjunction with CDC, to be used by the
grantees and CDC in assessing the
quality of the services provided within
VerDate jul<14>2003
18:04 May 23, 2005
Jkt 205001
the demonstration programs.
Submissions will be similar to data
received from grantees described above
in (b), but will be aggregate, and not
individual-level. Grantees may be asked
by CDC to submit individualized data if
submitted aggregate data do not meet
quality indicator standards.
d. All programs will submit annual
program-level data to CDC to be used to
monitor cost and cost-effectiveness,
funding sources, program design and an
increase in population-based screening
over the three year program period for
the geographically-defined area chosen
by the grantee. The types of data
included in Draft Table B–2, ‘‘ProgramRelated Data Elements,’’ variable
domains 1–4, will be required for
submission to CDC (program costs,
funding sources, description of health
care delivery systems and populationlevel screening prevalence data). Final
data elements used to obtain this
information will be agreed upon by CDC
and the grantees.
e. The remaining variable domains
from both tables are proposed items that
grantees may choose to collect. If
programs would like to collect data
items beyond those outlined in
Attachment B, they will need to provide
justification.
Performance will be measured based
upon: (1) The extent to which tracking
and data collection procedures are in
use and form the basis for quality
assurance processes; and (2) the
submission of timely and complete data
to CDC.
7. Patient Support
Programs will establish a patient
support system to assure that
appropriate screening services are
offered, appropriate diagnostic followup is received, appropriate treatment is
begun, and that any appropriate services
necessary but not provided by the
program are begun, such as triaging
patients with GI symptoms out of the
screening program, to be seen
immediately for appropriate diagnostic
testing. A system for the follow-up and
referral of a person whose screening test
results are abnormal or suspicious is an
essential component of any
comprehensive early detection program.
In some instances, diagnostic testing can
be accomplished during the screening
test (e.g., if colonoscopy is used). Clients
needing treatment services should be
counseled about their eligibility for
public-supported third party payment
and reimbursement programs, if such
programs exist. Activities under patient
support should include:
• Follow-up of positive screening test
results. If any of the program-selected
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
screening tests other than colonoscopy
are positive, they should be followed by
a diagnostic colonoscopy.
• Triage of patients to the appropriate
health care provider if they are found to
have GI symptoms at program
enrollment.
• Triage of patients to the appropriate
health care provider if they are found to
be at increased risk for CRC at program
enrollment.
• Referral of patients for staging or
treatment. Programs must provide
appropriate referrals for medical
treatment of persons screened in the
program and must ensure, to the extent
practicable, the provision of appropriate
follow-up services.
Performance will be measured by the
extent to which the program establishes
a system for patient support to assure
appropriate follow-up and referral.
8. Evaluation of the Effectiveness of the
Program
Design an evaluation plan to be used
to conduct evaluation of demonstration
program activities and improve the
quality, effectiveness and efficiency of
program operations.
Performance will be measured by the
extent to which programs use objective,
quantitative measures to demonstrate
the accomplishment of program goals,
objectives, and intended outcomes and
to make program improvements.
9. Other
Programs may identify other activities
that they must pursue in order to
effectively increase CRC screening in
their geographically-defined area and
the priority population. Such activities,
along with their justification, must be
fully described in the application,
particularly if funding for those
activities is being sought.
We anticipate that all funded
programs will include the same basic
program activities, although the focus of
the activities may differ slightly across
programs. Because applicant needs may
differ, not all programs will require
funding for every program activity.
In a cooperative agreement, CDC staff
is substantially involved in the program
activities, above and beyond routine
grant monitoring.
CDC Activities for this program are as
follows:
• Provide technical assistance to
recipients in the development,
administration, and evaluation of the
program efforts to implement organized
community-based CRC screening
demonstration programs.
• Assist in the adaptation of existing
data collection strategies and tools to be
able to collect data to monitor program
E:\FR\FM\24MYN1.ROB
24MYN1
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
effectiveness and tracking for this CRC
screening demonstration program.
Before screening services are offered
under this program, CDC will evaluate
proposed data collection plans.
• Evaluate aggregate patient and
program-level data received by the
grantees and use the results so that CDC
can follow program activities and
provide quality assurance, help grantees
strengthen their programs, make midcourse corrections and document
successes. For grantees who only submit
aggregate patient-level data (those who
do NOT receive CDC funds for
screening), if submitted aggregate
patient-level data do not meet quality
indicator standards, CDC may request
individualized data and will work with
the grantee to resolve data questions.
• Review and assist with refining the
evaluation plan designed/proposed by
the grantee to make sure it will be
adequate to monitor the goals and
objectives of this program. Work closely
with grantees throughout the three year
funding period to assist programs with
evaluation of their demonstration
programs and to assure adequate
documentation of successes and sharing
of applicable strategies and tools across
programs.
• Work with grantees to finalize a set
of data quality indicators to be used by
the grantees and CDC in assessing the
quality of the services provided within
the demonstration programs.
• Within the first six months, advise
on the design of a data collection
approach, to make sure that the
proposed approach is reasonably certain
to achieve the goals of this program.
Determine with the funded program that
screening services and data collection
are ready to begin.
• Provide patient and health care
provider education materials from
CDC’s Screen for Life: National
Colorectal Cancer Action Campaign,
such as brochures, fact sheets, medical
office displays, etc. which can be
adapted as necessary.
• Regularly review the literature to
ensure that grantees are being provided
technical assistance and consultation
that reflects the most up-to-date science
and practice.
• Convene a CRC Demonstration
Screening Program Workgroup, to help
oversee program activities and address
clinical and other issues.
• Convene a meeting of the funded
programs for information sharing,
problem solving, and training at least
annually.
• Conduct a site visit within the first
six months of award to assure program
readiness, and subsequently, to assess
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
program progress and mutually resolve
problems, as needed.
• Assess program readiness by
addressing the following issues: (1) The
identification of providers to perform
screening and follow-up service, and to
provide care in the event of
unanticipated complications; (2) a final
data collection and tracking system; (3)
a plan and funding sources to provide
treatment for those persons in whom
cancers are identified; (4) a plan for the
use of quality indicators to evaluate the
appropriate use of clinical services and
(5) a plan for recruiting individuals for
screening in their geographicallydefined area and the priority
population.
II. Award Information
Type of Award: Cooperative
Agreement. CDC involvement in this
program is listed in the Activities
Section above.
Fiscal Year Funds: 2005.
Approximate Total Funding:
$2,000,000.
Approximate Number of Awards:
Three to Five.
Approximate Average Award:
$600,000. (This amount is for the first
12-month budget period, and includes
both direct and indirect costs.)
Floor of Award Range: None.
Ceiling of Award Range: None.
Anticipated Award Date: August,
2005.
Budget Period Length: 12 months.
Project Period Length: Three years.
Throughout the project period, CDC’s
commitment to continuation of awards
will be conditioned on the availability
of funds, evidence of satisfactory
progress by the recipient (as
documented in required reports), and
the determination that continued
funding is in the best interest of the
Federal Government.
III.1. Eligible Applicants
To be eligible, applicants must
demonstrate a relationship with a CDC
funded CCC program (implementation
level) within their state(s). Applicants
will need to clearly define the
geographic area covered by their
proposed program.
Applications may be submitted by
public and private nonprofit
organizations and by governments and
their agencies, such as:
• Public nonprofit organizations
• Private nonprofit organizations
• Universities
• Colleges
• Research institutions
• Hospitals
Frm 00037
Fmt 4703
Sfmt 4703
• Community-based organizations
• Cancer Centers
• Community Health Centers
• Regional Hospital Systems
• Large Physician Group Practices
• Health Maintenance Organizations
• Large Public Employers, that do not
provide coverage for cancer screenings
• Defined Metropolitan Areas
• Rural health organizations/
consortia
• Multi-federal agency consortium
covering a defined geographic area
• Other large defined health care
systems
• Federally recognized Indian tribal
governments
• Indian tribes
• Indian tribal organizations
• State and local governments or their
Bona Fide Agents (this includes the
District of Columbia, the
Commonwealth of Puerto Rico, the
Virgin Islands, the Commonwealth of
the Northern Marianna Islands,
American Samoa, Guam, the Federated
States of Micronesia, the Republic of the
Marshall Islands, and the Republic of
Palau)
• Political subdivisions of States (in
consultation with States)
A Bona Fide Agent is an agency/
organization identified by the state as
eligible to submit an application under
the state eligibility in lieu of a state
application. If you are applying as a
bona fide agent of a state or local
government, you must provide a letter
from the state or local government as
documentation of your status. Place this
documentation behind the first page of
your application form.
III.2. Cost Sharing or Matching
Matching funds are not required for
this program.
III.3. Other
Special Requirements
III. Eligibility Information
PO 00000
29751
If your application is incomplete or
non-responsive to the special
requirements listed in this section, it
will not be entered into the review
process. You will be notified that your
application did not meet submission
requirements.
• Late applications will be considered
non-responsive. See section ‘‘IV.3.
Submission Dates and Times’’ for more
information on deadlines.
• To be eligible, applicants must
demonstrate a relationship with a CDCfunded CCC program (implementation
level) within their state(s) by providing
a letter of support (in the application
appendices) from the CDC funded CCC
program (implementation level)
indicating support for the CRC
E:\FR\FM\24MYN1.SGM
24MYN1
29752
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
demonstration screening program.
Applications that do not contain a letter
of support from the CDC funded CCC
program (implementation level) will not
be considered for review. More than one
application can be submitted per state,
but only one application per state will
be selected by CDC. Applicants will
need to clearly define the geographic
area that their program will cover.
Note: Title 2 of the United States Code
Section 1611 states that an organization
described in Section 501(c)(4) of the Internal
Revenue Code that engages in lobbying
activities is not eligible to receive Federal
funds constituting an award, grant, or loan.
IV. Application and Submission
Information
IV.1. Address To Request Application
Package
To apply for this funding opportunity
use application form PHS 5161–1.
CDC strongly encourages you to
submit your application electronically
by utilizing the forms and instructions
posted for this announcement at
https://www.grants.gov.
Application forms and instructions
are available on the CDC Web site, at the
following Internet address: https://
www.cdc.gov/od/pgo/forminfo.htm.
If you do not have access to the
Internet, or if you have difficulty
accessing the forms on-line, you may
contact the CDC Procurement and
Grants Office Technical Information
Management Section (PGO–TIM) staff
at: 770–488–2700. Application forms
can be mailed to you.
IV.2. Content and Form of Submission
Letter of Intent (LOI): Your LOI must
be written in the following format:
• Maximum number of pages: Two
• Font size: 12-point unreduced
• Single spaced
• Paper size: 8.5 by 11 inches
• Page margin size: One inch
• Printed only on one side of page
• Written in plain language, avoid
jargon
Your LOI must contain the following
information:
• Program title and number listed in
this RFA
• Type of organization submitting the
application
• Name of the organization
submitting the application
• Amount of funding request
• Official contact person’s name,
telephone number, fax number, mailing
address and e-mail address
Application: You must submit a
project narrative with your application
forms. The narrative must be submitted
in the following format:
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
• Maximum number of pages: 30. If
your narrative exceeds the page limit,
only the first pages which are within the
page limit will be reviewed.
• Font size: 12 point unreduced
• Double spaced
• Paper size: 8.5 by 11 inches
• Page margin size: One inch
• Printed only on one side of page
• Held together only by rubber bands
or metal clips; not bound in any other
way.
All activities designed to reach the
objectives of the RFA need to be
described. Even if an applicant
determines that one or several preexisting program activities do not
require CDC resources, a description of
those activities must be included in the
application, and those elements will be
evaluated.
Your narrative should address
activities to be conducted over the
entire project period, and must include
the following items in the order listed:
Executive Summary
Applicants should provide a clear,
concise one to two page summary to
include:
• Description of the community
where the program will take place,
including the geographic boundaries.
• A short description of existing or
proposed CRC screening program,
including priority population to be
screened.
• Amount of funding requested.
Background and Need
Describe the need for this program
within the proposed geographicallydefined population and among the
priority population. The following
information should be included:
• Description and size of larger
geographically-defined population and
the priority population for the program
(if a different priority population is
chosen from what is defined in this
RFA, the applicant must provide a
justification for choosing that priority
population).
• Description of the burden of CRC
within the community/population.
• Proportion of the priority
population currently screened.
Existing and Proposed Program
Description (including Capacity)
Describe the existing and/or proposed
program in detail including:
• All program components, including
those outlined in the ‘‘Activities’’
section of this RFA and any additional
activity proposed by the applicant.
• Which program activities are
already existing (if any) and which will/
will not be supported by CDC funding.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
• Methods for data collection
designed to show an increase in
screening in both the geographically
defined population and the priority
population. Include a list of proposed
data elements, a proposed plan to gather
those data, and plans for assuring data
security, protecting patient
confidentiality and de-identifying data.
• Which screening and diagnostic
tests will be used and the rationale for
the selection of screening and diagnostic
tests.
• The number of new clients
expected to be screened.
• A description of how the priority
population will be reached.
• Overall capability of providing the
program, including the applicant’s
history and experience with proposed
activities and services related to
providing colorectal screening.
• The capacity to offer these tests to
the intended audience, including the
identification of providers and a followup/referral plan.
Program Management
Describe the organization’s structure
and function, size, activities and
methods of routine communication with
staff. Describe each current or proposed
staff position for this initiative by job
title, function, education and
experience, general duties, and
activities with which that position will
be involved. Describe a proposed fiscal
system to track and monitor program
expenditures and to ensure the accurate
and timely reimbursement of services
provided by the program.
Workplan
The applicant should provide a
detailed work plan for the first year that
describes how the proposed activities
will be conducted. The work plan
should include the following:
• Objectives: Specific, realistic, timephased and measurable short-term (one
year) and long-term (three year)
objectives consistent with the intent of
this program announcement, including
targets for screening. The first six
months will be for start up, to include
finalizing the data collection system
with CDC, finalizing the evaluation plan
with CDC, and implementing all start up
activities so that service delivery may
begin within six months of award.
• Activities: Specific activities and
strategies that will be undertaken to
achieve each of the proposed short-term
objectives during the budget period.
• Time Line: A time line for assessing
progress in meeting objectives.
• Staff Responsibility: Staff
responsible for completion of activities.
E:\FR\FM\24MYN1.SGM
24MYN1
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
• Measures of Effectiveness: How
activities and their impact will be
evaluated, including indicators of
program success.
• Data: A list of sources that will be
used to gather information on measures
of effectiveness.
Grantees may choose to use the
attached work plan format to present
this information (See Attachment C of
this RFA).
Collaborative Activities
Describe existing or proposed
partnership to support the program,
including linkages with the appropriate
CCC implementation program(s) and
coalition partners. Describe a process for
maintaining a relationship with the CCC
program/coalition and ensuring that
program activities are aligned with CCC
plan strategies related to CRC. Provide
a letter of support from the CCC
Coalition that: (1) Verifies that the
applicant’s proposal aligns with CRC
priorities as defined in the Cancer Plan;
and (2) describes methods by which
Coalition or individual members will be
engaged in the demonstration CRC
screening program.
Evaluation
The applicant should describe
existing or proposed evaluation
activities. Using this outline and CDC’s
draft evaluation plan, the applicant will
work with CDC to finalize an evaluation
plan to be completed within the first six
months of award. This evaluation plan
will be used by the program with CDC
to evaluate each program goal and
objective and to use the evaluation
results to improve program
effectiveness. Describe who will be
responsible for conducting evaluation
activities and working with CDC on a
formal evaluation of the program.
Budget and Justification (Narrative
Justification Will Not Be Counted
Toward Application Page Limit)
Provide a detailed line item budget
and narrative justification of all
operating expenses consistent with the
proposed objectives and planned
activities. Each budget item should be
clearly related to a stated activity.
Participation in CDC sponsored
training, workshops, or meetings is
essential to the effective implementation
of this program. Travel funds should be
budgeted for the following meetings:
• One to two persons to Atlanta,
Georgia to discuss program
implementation progress (reverse site
visit) and for consultation and technical
assistance (two days, one trip per year.)
• Up to two additional two-person
trips to Atlanta, or other destinations to
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
attend or assist with national
workgroups, task forces, or committees
(one to three days.)
Additional information may be
included in the application appendices.
The appendices will not be counted
toward the narrative page limit. This
additional information includes:
• Curriculum vitae.
• Job descriptions.
• Organizational charts.
• Letters of support.
• Any other supporting
documentation.
You are required to have a Dun and
Bradstreet Data Universal Numbering
System (DUNS) number to apply for a
grant or cooperative agreement from the
Federal government. The DUNS number
is a nine-digit identification number,
which uniquely identifies business
entities. Obtaining a DUNS number is
easy and there is no charge. To obtain
a DUNS number, access https://
www.dunandbradstreet.com or call 1–
866–705–5711. For more information,
see the CDC Web site at: https://
www.cdc.gov/od/pgo/funding/
pubcommt.htm.
If your application form does not have
a DUNS number field, please write your
DUNS number at the top of the first
page of your application, and/or include
your DUNS number in your application
cover letter.
Additional requirements that may
require you to submit additional
documentation with your application
are listed in section ‘‘VI.2.
Administrative and National Policy
Requirements.’’
IV.3. Submission Dates and Times
LOI Deadline Date: June 8, 2005.
CDC requests that you send a LOI if
you intend to apply for this program.
Although the LOI is not required, is not
binding, and does not enter into the
review of your subsequent application,
the LOI will be used to gauge the level
of interest in this program, and to allow
CDC to plan the application review.
Application Deadline Date: July 8,
2005.
Explanation of Deadlines:
Applications must be received in the
CDC Procurement and Grants Office by
4 p.m. Eastern Time on the deadline
date.
You may submit your application
electronically at https://www.grants.gov.
Applications completed online through
Grants.gov are considered formally
submitted when the applicant
organization’s Authorizing Official
electronically submits the application to
www.grants.gov. Electronic applications
will be considered as having met the
deadline if the application has been
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
29753
submitted electronically by the
applicant organization’s Authorizing
Official to Grants.gov on or before the
deadline date and time.
If you submit your application
electronically with Grants.gov, your
application will be electronically time/
date stamped, which will serve as
receipt of submission. You will receive
an e-mail notice of receipt when CDC
receives the application.
If you submit your application by the
United States Postal Service or
commercial delivery service, you must
ensure that the carrier will be able to
guarantee delivery by the closing date
and time. If CDC receives your
submission after closing due to: (1)
Carrier error, when the carrier accepted
the package with a guarantee for
delivery by the closing date and time, or
(2) significant weather delays or natural
disasters, you will be given the
opportunity to submit documentation of
the carriers guarantee. If the
documentation verifies a carrier
problem, CDC will consider the
submission as having been received by
the deadline.
If you submit a hard copy of your
application, CDC will not notify you
upon receipt of your submission. If you
have a question about the receipt of
your LOI or application, first contact
your courier. If you still have a question,
contact the PGO–TIM staff at: 770–488–
2700. Before calling, please wait two to
three days after the submission
deadline. This will allow time for
submissions to be processed and logged.
This announcement is the definitive
guide on LOI and application content,
submission address, and deadline. It
supersedes information provided in the
application instructions. If your
submission does not meet the deadline
above, it will not be eligible for review,
and will be discarded. You will be
notified that you did not meet the
submission requirements.
IV.4. Intergovernmental Review of
Applications
Executive Order 12372 does not apply
to this program.
IV.5. Funding restrictions
Restrictions, which must be taken into
account while writing your budget, are
as follows:
• Funds may not be used for research.
• Reimbursement of pre-award costs
is not allowed.
• Funds may not be used for the
purchase or lease of land or buildings,
construction of facilities, renovation of
existing space.
• Funds may not be used for the
endorsement or promotion of any drugs,
E:\FR\FM\24MYN1.SGM
24MYN1
29754
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
health products, or medical supplies
and equipment.
• Funds may be used to support
personnel and to purchase supplies and
services directly related to program
activities consistent with the scope of
this announcement. While the purchase
of equipment is discouraged, it will be
considered for approval if justified on
the basis of being essential to the
program and not available from another
source.
If you are requesting indirect costs in
your budget, you must include a copy
of your indirect cost rate agreement. If
your indirect cost rate is a provisional
rate, the agreement should be less than
12 months of age.
Guidance for completing your budget
can be found on the CDC Web site, at
the following Internet address: https://
www.cdc.gov/od/pgo/funding/
budgetguide.htm.
by the deadline, the electronic version
will be considered the official
submission.
It is strongly recommended that you
submit your grant application using
Microsoft Office products (e.g.,
Microsoft Word, Microsoft Excel, etc.). If
you do not have access to Microsoft
Office products, you may submit a PDF
file. Directions for creating PDF files can
be found on the Grants.gov Web site.
Use of file formats other than Microsoft
Office or PDF may result in your file
being unreadable by our staff;
Or
Submit the original and two hard
copies of your application by mail or
express delivery service to: Technical
Information Management-RFA AA030,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341.
IV.6. Other Submission Requirements
LOI Submission Address: Submit your
LOI by express mail, delivery service,
fax, or E-mail to: Tanya Hicks, Centers
for Disease Control and Prevention,
National Center for Chronic Disease
Prevention and Health Promotion, 4770
Buford Highway, MS K–57, Atlanta,
Georgia 30341. Telephone: (770) 488–
4325. Fax: (770) 488–3230. E-mail:
THicks@cdc.gov.
Application Submission Address:
CDC strongly encourages applicants to
submit electronically at: https://
www.grants.gov. You will be able to
download a copy of the application
package from https://www.grants.gov,
complete it offline, and then upload and
submit the application via the
Grants.gov site. E-mail submissions will
not be accepted. If you are having
technical difficulties in Grants.gov, they
can be reached by e-mail at
support@grants.gov or by phone at 1–
800–518–4726 (1–800–518–GRANTS).
The Customer Support Center is open
from 7 a.m. to 9 p.m. Eastern Time,
Monday through Friday.
CDC recommends that you submit
your application to Grants.gov early
enough to resolve any unanticipated
difficulties prior to the deadline. You
may also submit a back-up paper
submission of your application. Any
such paper submission must be received
in accordance with the requirements for
timely submission detailed in Section
IV.3. of the grant announcement. The
paper submission must be clearly
marked: ‘‘BACK-UP FOR ELECTRONIC
SUBMISSION.’’
The paper submission must conform
to all requirements for non-electronic
submissions. If both electronic and
back-up paper submissions are received
V. Application Review Information
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
V.1. Criteria
Applicants are required to provide
measures of effectiveness that will
demonstrate the accomplishment of the
various identified objectives of the
cooperative agreement. Measures of
effectiveness must relate to the
performance goals stated in the
‘‘Purpose’’ section of this
announcement. Measures must be
objective and quantitative, and must
measure the intended outcome. These
measures of effectiveness must be
submitted with the application and will
be an element of evaluation.
Your application will be evaluated
against the following criteria:
Existing and Proposed Program
Description (Including Capacity) (30
Points)
(a) Overall preparedness (5 points):
Does the applicant describe its
capability to carry out the proposed
objectives of this program, including
demonstrating past success with similar
programs?
(b) Reaching population to be served
(5 points): Does the applicant propose a
projected number of screens or a
proportional target increase in
screening? Does the applicant outline a
plan to reach and recruit both the larger
population in the geographically
defined area and the priority
population?
(c) Description of program
components (10 points): Does the
applicant include a description of all
program components (including data
collection and tracking, quality
assurance and professional
development, case management, public
education and outreach, and other
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
proposed activities) and indicate which
will/will not be supported by CDC
funding? Are methods for data
collection designed to show an increase
in screening in both the geographically
defined population and the priority
population described? Are a list of
proposed data elements, a proposed
plan to gather those data elements, and
plans for assuring data security,
protecting patient confidentiality and
de-identifying data included?
(d) Description of tests to be used
within demonstration program (5
points): Are the screening and
diagnostic tests selected adequately
described, including a rationale for
selection? Are the proposed tests
consistent with USPSTF guidelines?
Does the applicant describe adequate
availability of selected tests and
demonstrate the capacity to offer these
tests?
(e) Treatment and complications (5
points): Has the applicant addressed
how clients will be offered treatment if
a cancer is detected, and how
complications will be managed?
Work Plan (20 Points)
(a) Appropriate objectives (10 points):
Are proposed short-term (one year) and
long-term (three year) objectives
specific, time-phased, measurable,
realistic, related to identified needs and
consistent with the purpose of this
program announcement?
(b) Appropriate strategies (10 points):
Does the applicant’s plan for achieving
the proposed activities appear realistic
and feasible and relate to the
programmatic requirements and
purposes of this program
announcement?
Collaborative Activities (20 Points)
(a) Linkage with CCC (10 points): Is a
linkage established with a CDC-funded
CCC implementation program(s) and
coalition? Does the applicant provide a
letter of support from the CCC program/
coalition providing details of its
relationship to the applicant and
commitment to ensuring linkages to
CCC plan implementation?
(b) Working with diverse partners (10
points): Does the applicant describe
clear and complete plans to develop or
maintain active working relationships
with other organizations, agencies, or
partners in the design and
implementation of the program?
Evaluation (10 Points)
Do the proposed evaluation activities
address progress toward meeting goals
and objectives, describe indicators of
program success, and appear to be
reasonable and feasible? Does the
E:\FR\FM\24MYN1.SGM
24MYN1
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
applicant describe how evaluation
results will be used to improve program
effectiveness? Do they describe who will
be responsible for evaluation activities?
Program Management (10 Points)
Does the applicant describe the
organization’s size, structure and
function? Does the applicant
demonstrate ability to manage the
project, including clear lines of
communication and organizational
support? Is each current or proposed
staff position for this initiative
described (including job title, function,
required education and experience,
general duties, and activities with
which that position will be involved)?
Does the applicant describe a proposed
fiscal system to track and monitor
program expenditures and to ensure the
accurate and timely reimbursement of
services provided by the program?
Background and Need (10 Points)
For applicants addressing populationbased CRC screening among persons 50
years and older in a geographically
defined area, and focusing screening
efforts on persons 50 years and older
with low incomes and inadequate or no
health insurance coverage for CRC
screening (priority population):
Does the applicant adequately
describe the need for this program? Does
the applicant define the geographic area
that their program will cover? Are the
characteristics and the size of the
defined priority population described?
Is the burden of cancer among the
community and the priority population
described? Is the current CRC screening
test prevalence of persons in the defined
geographic area and the priority
population described?
Or,
For applicants addressing populationbased CRC screening among persons 50
years and older in a geographically
defined area, and focusing screening
efforts on a priority population other
than persons 50 years and older with
low incomes and inadequate or no
health insurance coverage for CRC
screening:
Does the applicant adequately
describe the need for this program? Does
the applicant define the geographic area
that their program will cover? Are the
characteristics and the size of the
defined priority population described?
Does the applicant provide a
justification for selecting a priority
population different from the priority
population defined in this RFA? Is the
burden of cancer among the community
and the priority population described?
Is the current CRC screening test
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
prevalence of persons in the defined
geographic area and the priority
population described?
Executive Summary (Not Scored)
Does the applicant provide an
executive summary that describes the
community the program will cover, a
short description of the proposed
program and the amount of funding
requested?
Budget and Justification (Not Scored)
Is the budget well defined, reasonable,
and consistent with the purpose of the
program and the activities proposed? Is
a narrative justification provided? Are
required travel funds requested?
V.2. Review and Selection Process
Applications will be reviewed for
completeness by the Procurement and
Grants Office (PGO) staff and for
responsiveness by the Division of
Cancer Prevention and Control.
Incomplete applications and
applications that are non-responsive to
the eligibility criteria will not advance
through the review process. Applicants
will be notified that their application
did not meet submission requirements.
An objective review panel will
evaluate complete and responsive
applications according to the criteria
listed in the ‘‘V.1. Criteria’’ section
above. Applications will be funded in
order by score and rank determined by
the review panel.
V.3. Anticipated Announcement and
Award Dates
Anticipated date of award is August
31, 2005.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a
Notice of Award (NoA) from the CDC
Procurement and Grants Office. The
NoA shall be the only binding,
authorizing document between the
recipient and CDC. The NoA will be
signed by an authorized Grants
Management Officer, and mailed to the
recipient fiscal officer identified in the
application.
Unsuccessful applicants will receive
notification of the results of the
application review by mail.
VI.2. Administrative and National
Policy Requirements
45 CFR Part 74 and Part 92
For more information on the Code of
Federal Regulations, see the National
Archives and Records Administration at
the following Internet address: https://
www.access.gpo.gov/nara/cfr/cfr-tablesearch.html.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
29755
The following additional
requirements apply to this project:
• AR–8 Public Health System
Reporting Requirements.
• AR–9 Paperwork Reduction Act
Requirements.
• AR–10 Smoke-Free Workplace
Requirements.
• AR–11 Healthy People 2010.
• AR–12 Lobbying Restrictions.
• AR–14 Accounting System
Requirements.
• AR–15 Proof of Non-Profit Status.
• AR–24 Health Insurance
Portability and Accountability Act
Requirements.
• AR–25 Release and Sharing of
Data.
Additional information on these
requirements can be found on the CDC
Web site at the following Internet
address: https://www.cdc.gov/od/pgo/
funding/ARs.htm.
An additional Certifications form
from the PHS 5161–1 application needs
to be included in your Grants.gov
electronic submission only. Refer to
https://www.cdc.gov/od/pgo/funding/
PHS5161–1Certificates.pdf. Once the
form is filled out, attach it to your
Grants.gov submission as Other
Attachment Forms.
VI.3. Reporting Requirements
You must provide CDC with an
original, plus two hard copies of the
following reports:
1. Interim progress report, due no less
than 90 days before the end of the
budget period. The progress report will
serve as your non-competing
continuation application, and must
contain the following elements:
a. Current Budget Period Activities
Objectives.
b. Current Budget Period Financial
Progress.
c. New Budget Period Program
Proposed Activity Objectives.
d. Budget for new budget period.
e. Measures of Effectiveness.
f. Additional Requested Information.
2. Financial status report and annual
progress report, no more than 90 days
after the end of the budget period.
3. Final financial and performance
reports, no more than 90 days after the
end of the project period.
These reports must be mailed to the
Grants Management or Contract
Specialist listed in the ‘‘Agency
Contacts’’ section of this announcement.
Additional Reporting Requirements
Patient-related and program-related
data (as defined in the ‘‘Activities,’’
‘‘Data Collection and Tracking’’ section
of this RFA) is due to CDC on a routine
basis.
E:\FR\FM\24MYN1.SGM
24MYN1
29756
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
• All programs will submit programrelated data annually (June 1).
• Programs receiving CDC funds for
screening services will submit aggregate
patient-related data quarterly (March 1,
June 1, October 1 and December 1), but
be required to switch to submission of
individual patient-related data during
the 3 year program period, pending
approval from OMB.
• Programs NOT receiving CDC funds
for screening services will submit
aggregate patient-related data quarterly
(March 1, June 1, October 1 and
December 1).
• In year 01 of the program, the first
patient-level data will be due March 1,
2006 and first program-related data will
be due June 1, 2006.
VII. Agency Contacts
We encourage inquiries concerning
this announcement. For general
questions, contact: Technical
Information Management Section, CDC
Procurement and Grants Office, 2920
Brandywine Road. Atlanta, GA 30341.
Telephone: 770–488–2700.
For program technical assistance,
Laura Seeff, MD, Centers for Disease
Control and Prevention, National Center
for Chronic Disease Prevention and
Health Promotion, 4770 Buford
Highway, MS K–55, Atlanta, Georgia
30341. 770–488–3223. E-mail address:
lseeff@cdc.gov;
Or
Leslie Given, MPA, Centers for
Disease Control and Prevention,
National Center for Chronic Disease
Prevention and Health Promotion, 4770
Buford Highway, MS K–57, Atlanta,
Georgia 30341. Telephone: (770) 488–
3099. E-mail address: lgiven@cdc.gov.
For financial, grants management, or
budget assistance, contact: Barbara Rene
Benyard, Grants Management Specialist,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341. Telephone: 770/488–2757. Email: bnb8@cdc.gov.
VIII. Other Information
This and other CDC funding
opportunity announcements can be
found on the CDC Web site, Internet
address: https://www.cdc.gov. Click on
‘‘Funding’’ then ‘‘Grants and
Cooperative Agreements.’’ Additional
information about CRC can be found at
the CDC Division of Cancer Prevention
and Control Web site https://
www.cdc.gov/cancer/colorctl/
index.htm.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
California
Colorado
Florida
Georgia
Hawaii
Iowa
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Missouri
Nebraska
New Jersey
New Mexico
New York
North Carolina
Northwest Portland Area Indian Health
Board
Ohio
Pennsylvania
Rhode Island
Texas
Utah
Virginia
Washington
West Virginia
Attachment B
Attachment A—CDC National
Comprehensive Cancer Control Program
Implementation Programs (as of March 1,
2005)
Alabama
Arkansas
TABLE B–1.—DRAFT PATIENT-RELATED DATA ELEMENTS
Variable domains
Possible data elements
1. Unique Identifiers ....................................................
• Patient identifier.
• Record identifier.
• Date of birth .............................................
2. Demographics .........................................................
3. Screening History ....................................................
4. Screening Information .............................................
• Gender.
• Race/ethnicity (collected as separate
fields).
• County of residence, state, zip code.
• Previous CRC test (FOBT, FIT,
colonoscopy etc.).
• Date and type of procedure provided ......
• Data on completion of screening (completed, refused etc.).
• Screening location (code for location) .....
• Complication of screening procedure ......
• Date of complication ................................
Samples of potential use of data elements
for
evaluation
• Proportion of individuals screened within
the specified program catchment area.
• Proportion of rarely/never screened participants.
• Date performed (month, year for each)
• Results for each (most recent result for
each test).
• Types of providers performing enrollment
and providing screening services patients).
• Types of screening tests provided.
• Characteristics of participants by type of
screening tests.
• Frequency of tests provided over time
(e.g., annual FOBT).
• Barriers to providing certain tests (i.e.,
what types of procedures are refused by.
• Results of tests.
• Recommended follow-up tests/diagnostic
procedures (if any).
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
E:\FR\FM\24MYN1.SGM
24MYN1
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
29757
TABLE B–1.—DRAFT PATIENT-RELATED DATA ELEMENTS—Continued
Variable domains
Possible data elements
5. Diagnostic Procedure(s) Provided (repeat for additional procedures).
• Data on completion of diagnostic procedures (completed, refused etc.).
• Date and type of follow-up procedure(s)
(e.g., colonoscopy, DCBE).
• Diagnosis location (code for location) .....
6. Cancer/Polp Diagnosis ............................................
• Complication of diagnostic procedure &
date..
• Results of tests. .......................................
• Recommendations for additional followup procedures.
• Status of final diagnosis ..........................
7. Treatment ................................................................
• Date & final diagnosis (polyp, cancer
etc.).
• Location of lesion. ....................................
• Histology. .................................................
• Number of polyps & size of largest lesion..
• Behavior (in-situ, invasive). .....................
• Stage of diagnosis (cancer only). ............
• Indicate how stage was determined. .......
• Stage from registry. .................................
• Status of treatment. .................................
8. Program and Enrollment Location ..........................
• Date treatment started. ............................
• Who is paying for treatment?
• Program ...................................................
9. CRC Cancer Risk Factors .......................................
• Enrollment site (code for location). ..........
• Family history of CRC .............................
• Personal history of CRC ..........................
• Personal history of polyps .......................
10. Reason for Obtaining Current Screening Test .....
• Personal history of high risk factors (e.g.,
IBD, genetic syndromes)..
• Reason for current visit (specific symptoms, routine screening, follow-up on
previous abnormal test).
• Did doctor recommend CRC screening?
Samples of potential use of data elements
for
evaluation
• Proportion of individuals with abnormal
results.
• Number of diagnostic tests performed.
• Specificity of screening tests, given results of follow-up (i.e., proportion of abnormal FOBTs that colonoscopy, require
follow-up and are shown to be ‘‘false
positive’’).
• Proportion of participants who are diagnosed with CRC.
• Proportion of participants who are identified with polyps.
• Proportion of participants who receive
treatment as indicated by guidelines.
• Proportion of individuals enrolled at specific locations.
• Proportion of people in high risk categories.
• Effect of outreach efforts on recruiting
high risk individuals.
• Relationship of personal and family history on screening behavior.
• Proportion of participants currently experiencing symptoms.
• Knowledge and attitude toward obtaining
CRC screening.
TABLE B–2.—DRAFT PROGRAM-RELATED DATA ELEMENTS
Variable domains
Possible data elements
Samples of potential use of data elements
for evaluation
1. Program Costs ........................................................
• Staff salary costs .....................................
• Variation in costs per person screened
by the program.
• Factors influencing increases in cost.
• Cost-effectiveness of innovative strategies used by the programs.
• Assessing potential economy of scale of
program structures.
• Consultant costs ......................................
• Cost of contracts (linked with by the program specific activities).
• Start-up costs (e.g., staff recruitment,
equipment).
• Training costs. .........................................
• Screening (FOBT, strategies used by
sigmoidoscopy, colonoscopy, DCBE) and
diagnosis costs.
• CM costs.
• Administrative costs.
• Costs to patients (e.g., co-pays).
• Cost or preparation for endoscopy.
• Cost of biopsies.
• Cost of complications.
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
E:\FR\FM\24MYN1.SGM
24MYN1
29758
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
TABLE B–2.—DRAFT PROGRAM-RELATED DATA ELEMENTS—Continued
Variable domains
Samples of potential use of data elements
for evaluation
Possible data elements
2. Funding Sources .....................................................
3. Description of Health Care Delivery System ..........
4. Population-level .......................................................
5. Outreach/Recruitment Process Talk to Ingrid Hall
in EARB about how she captures outreach categories.
•
•
•
•
Federal dollars .........................................
State funding ............................................
Private foundations.
In-kind contributions (type kind contributions and duration).
• How/with whose dollars is each program
area being paid for (FTEs, screening
services, etc).
• Types of providers (e.g., physicians—primary care or specialist—non-physician
provider) systems delivering screening
(e.g. HMO, cancer center, clinic, hospital) and diagnostic tests (does this belong here?)
• Reimbursement mechanisms ..................
• Program administrative.
• Past experience with CRC screening.
• E.g., BRFSS or other population level
data.
• General and priority population for outreach.
6. Eligibility Requirements ...........................................
• Types of outreach efforts used (e.g.,
health fair).
• Age, family income, and insurance status
criteria established by programs.
• (see note about FPL) ...............................
7. Professional Education ...........................................
• Topics of trainings provided ....................
8. Quality .....................................................................
• Target audience of training. .....................
• Number of attendees and sessions.
• Use of Medical Advisory Committee
(Mac) by grantees.
• Description of MAC activities ...................
9. Case Management (CM) .........................................
10. Partnerships ..........................................................
• Description of model used to deliver CM
services.
• Barriers to tracking those with abnormal
results.
• Duration of CM services (until diagnosis,
treatment, or thereafter.
• Types of partnerships established (e.g.,
community centers, minority organizations.
• Sources of funding for programs.
• Proportion of in-kind contributions.
• Relationship of provider specialty with
screening behavior, types of follow-up
procedures provided, etc.
• Cost-effectiveness of service delivery
structures.
• Population level measure of increase in
screening rates.
• Effectiveness of each type of outreach
effort.
• Effectiveness of outreach in recruiting
priority populations.
• Differences in insurance status criteria
eligibility criteria between programs.
• Number and types of patients recruited
based on the eligibility criteria established.
• Relationship of trainings offered and the
patterns of care over time (appropriateness of tests recommended; compliance
with CRC screening guidelines).
• Proportion of an active MAC.
• Extent to which a MAC is providing oversight to services provided (e.g., reviewing guidelines).
• Relationship of MAC involvement to
types of tests delivered.
• Proportion of participants in need of CM
services who actually receive them.
• CM models that are cost-effective.
• Factors influencing effective CM that can
be translated into strategies for all the
programs to implement.
• Identify efforts undertaken to screen priority populations.
Attachment C
WORKPLAN TEMPLATE
Goal
Objectives
Measures of
effectiveness
Activities
Data
Timeframe for assessing
progress
Goal
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
E:\FR\FM\24MYN1.SGM
24MYN1
Team members
responsible
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
29759
WORKPLAN TEMPLATE—Continued
Goal
Objectives
Measures of
effectiveness
Activities
Workplan—Definition of Terms
Goals
Goals are general, ‘‘big picture’’ statements
of outcomes a program intends to accomplish
to fulfill its mission.
Objectives
Objectives are the ‘‘big steps’’ a program
will take to attain its goals. Objectives should
be S.M.A.R.T. (specific, measurable,
achievable, realistic, and time-phased).
Activities
Activities are the ‘‘smaller steps’’ a
program takes to meet its objectives.
Examples include reviewing data and
research, identifying resources and staff for
program implementation and evaluation,
creating Public Service Announcements
about screening recommendations, and
health provider training about screening
technology.
Measures of Effectiveness
Measures of effectiveness, or indicators,
translate program concepts and expected
impacts into specific measures that can be
analyzed and interpreted. There should be at
least one measure of effectiveness for each
objective. The change measured by an
indicator should represent progress a
program has made toward achieving goals
and objectives.
Examples of indicators include:
participation rates, individual behavior,
health status, and attitude. Success in
achieving the goal of maintaining coalition
partnerships could be measured by analyzing
participation rates or the number of members
at the beginning, throughout and near the
end of plan implementation. An increase (or
decrease/no change) in participation rate
indicates level of progress toward meeting
the goal.
Data
Data is a list of sources that will be used
to gather information on measures of
effectiveness. Data sources may include:
People, observations and documents.
Examples of data sources include: Behavioral
Risk Factor Surveillance System (BRFSS),
Surveillance, Epidemiology, and End Results
(SEER), needs and satisfaction assessments,
program records and reports, cancer
registries, interviews, focus groups, and
medical claims data.
Attachment D—References for Centers for
Disease Control and Prevention RFA AA030,
Colorectal Cancer Screening Demonstration
Program
1. American Cancer Society. Cancer Facts
and Figures, 2005. Atlanta, Georgia:
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
Data
American Cancer Society, 2005 (publication
no. 5008.05).
2. Mandel JS, Bond JH, Church TR, Snover
DC, Bradley GM, Schuman LM, Ederer F.
Reducing mortality from colorectal cancer by
screening for fecal occult blood. Minnesota
Colon Cancer Control Study. N Engl J Med
1993;328:1365–71.
3. Mandel JS, Church TR, Bond JH, et al.
The effect of fecal occult-blood screening on
the incidence of colorectal cancer. N Engl J
Med 2000;343:1603–7.
4. Selby JV, Friedman GD, Quesenberry CP
Jr, Weiss NS. A case-control study of
screening sigmoidoscopy and mortality from
colorectal cancer. N Engl J Med 1992;
326:653–657.
5. Hardcastle JD, Chamberlain JO,
Robinson MH, et al. Randomised controlled
trial of faecal-occult-blood screening for
colorectal cancer. Lancet 1996; 348:1472–
1477.
6. Kronborg O, Fenger C, Olsen J, Jorgensen
OD, Sondergaard. Randomised study of
screening for colorectal cancer with faecaloccult-blood test. Lancet 1996; 348:1467–
1471.
7. Seeff LC, Nadel MR, Klabunde C,
Thompson T, Shapiro JA, Vernon SW, Coates
RJ. Patterns and Predictors of Colorectal
Cancer Test Use in the Adult U.S.
Population. Cancer 2004;100:2093–103.
[FR Doc. 05–10296 Filed 5–23–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Request for Applications (RFA) 05075]
Expansion and Support of HIV/AIDS/
STI/TB Information, Education, and
Communication and Behavioral
Change Communication Activities in
Ethiopia—Amendment
A notice announcing the availability
of fiscal year (FY) 2005 funds for
Expansion and Support of HIV/AIDS/
STI/TB Information, Education, and
Communication and Behavioral Change
Communication Activities in Ethiopia
was published in the Federal Register
on Tuesday, May 3, 2005, Volume 70,
Number 84, pages 22875–22881. The
notice is amended as follows:
Replace the current language, starting
in the second column on page 22879
through the first column of page 22880,
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Timeframe for assessing
progress
Team members
responsible
regarding Prostitution and Related
Activities with the following:
• Prostitution and Related Activities.
The U.S. Government is opposed to
prostitution and related activities,
which are inherently harmful and
dehumanizing, and contribute to the
phenomenon of trafficking in persons.
Any entity that receives, directly or
indirectly, U.S. Government funds in
connection with this document
(‘‘recipient’’) cannot use such U.S.
Government funds to promote or
advocate the legalization or practice of
prostitution or sex trafficking. Nothing
in the preceding sentence shall be
construed to preclude the provision to
individuals of palliative care, treatment,
or post-exposure pharmaceutical
prophylaxis, and necessary
pharmaceuticals and commodities,
including test kits, condoms, and, when
proven effective, microbicides. A
recipient that is otherwise eligible to
receive funds in connection with this
document to prevent, treat, or monitor
HIV/AIDS shall not be required to
endorse or utilize a multisectoral
approach to combating HIV/AIDS, or to
endorse, utilize, or participate in a
prevention method or treatment
program to which the recipient has a
religious or moral objection. Any
information provided by recipients
about the use of condoms as part of
projects or activities that are funded in
connection with this document shall be
medically accurate and shall include the
public health benefits and failure rates
of such use.
In addition, any recipient must have
a policy explicitly opposing prostitution
and sex trafficking. The preceding
sentence shall not apply to any ‘‘exempt
organizations’’ (defined as the Global
Fund to Fight AIDS, Tuberculosis and
Malaria, the World Health Organization,
the International AIDS Vaccine
Initiative or to any United Nations
agency).
The following definition applies for
purposes of this clause:
• Sex trafficking means the
recruitment, harboring, transportation,
provision, or obtaining of a person for
the purpose of a commercial sex act. 22
U.S.C. 7102(9).
All recipients must insert provisions
implementing the applicable parts of
E:\FR\FM\24MYN1.SGM
24MYN1
Agencies
[Federal Register Volume 70, Number 99 (Tuesday, May 24, 2005)]
[Notices]
[Pages 29747-29759]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-10296]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Colorectal Cancer Screening Demonstration Program
Announcement Type: New.
Funding Opportunity Number: RFA AA030.
Catalog of Federal Domestic Assistance Number: 93.283.
Key Dates: Letter of Intent (LOI) Deadline: June 8, 2005.
Application Deadline: July 8, 2005.
Executive Summary: Colorectal Cancer (CRC) is the second leading
cause of cancer-related deaths in the United States, following lung
cancer (1-American Cancer Society 2005, see Attachment D). Strong
scientific evidence indicates that regular screening is effective in
reducing CRC incidence and mortality (2--Mandel 1993, 3--Mandel 2000,
4--Selby 1992, 5--Kronburg 1996, 6--Hardcastle 1996, see Attachment D).
Screening rates for CRC are currently lower than other cancer
screening services (7--Seeff 2004). CRC screening is already occurring
in some communities, either in an organized or an opportunistic
setting. Some communities are planning to begin screening, but are
still building their infrastructure and/or resources.
The Centers for Disease Control and Prevention (CDC) announce the
availability of funds in fiscal year (FY) 2005 for three to five
cooperative agreements to implement demonstration programs designed to
increase population-based CRC screening among persons 50 years and
older in a geographically defined area, with screening efforts focused
on persons 50 years and older with low incomes and inadequate or no
health insurance coverage for CRC screening (priority population).
Applicants will need to define the geographic area that their program
will cover. Applicants will be asked to describe their current CRC
screening efforts and to define what they need to increase CRC
screening rates in these two populations: (1) The larger
geographically-defined population; and (2) the priority sub-population
within that geographically-
[[Page 29748]]
defined area. CDC will choose among applicants based on specific
evaluation criteria described in this RFA. These will be three year
demonstration programs, pending availability of funds.
I. Funding Opportunity Description
Authority: This program is authorized under section 317(k)(2) of
the Public Health Service Act, [42 U.S.C. section 247b(k)(2)], as
amended.
Background: Colorectal Cancer (CRC) is the second leading cause of
cancer-related deaths in the United States, following lung cancer (1).
Screening for CRC works both through the identification and removal of
precancerous polyps, and the early detection of cancers. Strong
scientific evidence indicates that regular screening is effective in
reducing CRC incidence and mortality (2-6). Randomized controlled
trials have demonstrated a reduction in CRC incidence and mortality
with annual and biennial fecal occult blood testing (FOBT) and case-
control studies have shown a reduction in CRC mortality associated with
the use of sigmoidoscopy. Indirect evidence supports the effectiveness
of colonoscopy and double-contrast barium enema (DCBE) for use as CRC
screening tests.
Based on scientific evidence, national guidelines have been
developed recommending regular CRC screening for average-risk persons
with one or more of the following options: FOBT, sigmoidoscopy, FOBT
and flexible sigmoidoscopy in combination; colonoscopy, and/or DCBE.
The U.S. Preventive Services Task Force (USPSTF) strongly recommends
that clinicians screen men and women 50 years of age or older for CRC
and give an ``A'' recommendation to regular CRC screening with one of
the above listed testing options. Fecal Immunochemical Testing (FIT) is
considered an acceptable alternative to FOBT. These tests vary in their
costs, availability, and associated risks, and current evidence does
not clearly demonstrate which of these tests is most effective.
National survey data show that only approximately half of eligible
adults have been screened for CRC according to recommended guidelines.
A number of factors are likely contributing to low screening rates
including: (1) Lack of knowledge by the public that CRC is common and
screening is effective; (2) lack of physician recommendations to get
regular screening; (3) lack of a regular health care provider; (4)
patient embarrassment, fear of cancer, poor reimbursement; (5) limited
insurance coverage for CRC screening or lack of insurance; and (6) lack
of organized systems where screening and follow-up may be conducted.
Other barriers may exist which are recognized in community settings but
not documented in published literature.
Purpose: The purpose of this program is to establish demonstration
programs to increase population-based CRC screening among persons 50
years and older in a geographically defined area, and to focus
screening efforts on persons with low incomes and inadequate or no
health insurance coverage for CRC screening. This program addresses the
``Healthy People 2010'' focus area Cancer, specifically to increase the
proportion of adults who receive a colorectal screening examination.
https://www.healthypeople.gov/Document/pdf/Volume1/03Cancer.pdf.
Measurable outcomes of the program will be: To increase the CRC
screening rate among persons 50 years and older in a geographically
defined area overall (as defined by the applicant), and among persons
50 years and older within that geographically-defined area with low
incomes and inadequate or no health insurance coverage for CRC
screening in particular. The CRC screening demonstration programs will
need to set their own goal for a projected increase in the number or
percentage of CRC screens. Screening rates using one or a combination
of the following tests will be measured: FOBT or FIT annually,
sigmoidoscopy every 5 years, FOBT and flexible sigmoidoscopy in
combination; colonoscopy every 10 years, and/or DCBE every 5 years. No
CDC Government Performance and Results Act (GPRA) measure currently
addresses CRC screening.
This announcement is only for non-research activities supported by
CDC/ATSDR. If research is proposed, the application will not be
reviewed. For the definition of research, please see the CDC Web site
at the following Internet address: https://www.cdc.gov/od/ads/
opspoll1.htm.
Special Guidance for Technical Assistance: Technical assistance
will be available for potential applicants on two one-hour conference
calls, one morning and one evening, scheduled one week after the LOIs
are due. Please call 1-888-455-5920 and enter conference passcode 50260
at 3 p.m. EST on Wednesday June 22, 2005 or 1-888-455-5920 and enter
conference passcode 32070 at 9 a.m. on Thursday June 23, 2005.
Activities: Cooperative agreement applicants do not have to request
funding for each of the program components described below. Awardee
activities for this program may include, but are not limited to the
activities listed below:
1. Program Management
a. Establish specific, measurable, and realistic short-term (one
year) and long-term (three year) objectives consistent with the purpose
of this program announcement for the accomplishment of the program
activities, including the establishment of realistic screening goals.
b. Recruit and develop staff to maintain the program.
c. Develop a fiscal system that tracks and monitors program
expenditures and ensures the accurate and timely reimbursement of
services provided by the program.
d. Develop accurate budget requests that correspond with program
workplans and prepare/submit required reports on a timely basis.
Performance will be measured by the extent to which the program (1)
establishes specific, measurable and realistic objectives (including
realistic screening goals); (2) hires/identifies and maintains
qualified staff; (3) spends funding efficiently and effectively; and
(4) effectively addresses problems as they arise.
2. Provision of Screening and Diagnostic Follow-up Services
a. Provide CRC screening and diagnostic follow-up services for
persons 50 years and older with low incomes and inadequate or no health
insurance coverage for CRC screening in organized, CRC screening
demonstration programs. A more specific priority population can be
proposed if this can be justified. The level of poverty of the priority
population will be defined by the applicant (typically at or below 250
percent or 200 percent of the Federal poverty level). In the absence of
data suggesting which screening test is most effective, grantees will
be given flexibility in the selection of screening tests with two
important caveats: (1) Grantees can only offer screening tests for
which test availability has been assessed and capacity has been
demonstrated; and (2) grantees can only offer screening tests
recommended by the U.S. Preventive Services Task Force (USPSTF). Since
FIT is considered an acceptable alternative to FOBT, it will be a
reimbursable service within these programs as an alternative to FOBT,
if the program desires. Acceptable tests include:
Guaiac-based FOBT annually (at-home only).
[[Page 29749]]
Immunochemical FOBT (FIT annually will be considered as an
alternative to FOBT).
Flexible sigmoidoscopy every five years.
Double-contrast barium enema every five years.
Colonoscopy every ten years.
b. Implement a program design that offers a single screening test
or multiple screening tests. The selection of screening tests offered
in the demonstration program may change over the three year period
pending prior approval and availability of funds, if a program finds
that a test is not in demand among the priority populations or if a
newer test is added to USPSTF guidelines during the funding period.
c. Demonstrate readiness to begin offering screening services
within six months of award. Elements which will be evaluated to
determine readiness include: (1) The identification of providers to
perform screening and follow-up service, and to provide care in the
event of unanticipated complications; (2) a plan to recruit persons for
screening from the larger geographically-defined population and the
priority population; (3) a final set of data quality indicators,
defined in collaboration with CDC, to be used by the grantees and CDC
in assessing the quality of the services provided within the
demonstration programs; (4) a final data collection and tracking
system; and (5) a plan and funding sources to provide treatment for
those persons in whom cancers are identified. CDC will make a site
visit within six months of award to assess readiness and approve
commencement of screening activities.
Performance will be measured by the extent to which the applicant
(1) increases the number of people screened within both the defined
geographic area and the priority population; and (2) meets the
projected number of screens or the proportional increases in screening
as set by the program.
3. Public Education and Outreach
a. Develop and carry out strategies to increase awareness about CRC
screening including building on existing public education efforts at
the local, state and national level that are consistent with evidence-
based interventions recommended in the Community Guide to Preventive
Services. Programs may utilize campaign materials from CDC's Screen for
Life: National Colorectal Cancer Action Campaign ``Screen for Life,''
which can be tagged for individual program use.
b. Develop and implement an outreach workplan that includes a mix
of broad-based activities and one-on-one outreach, using methods known
to be effective in reaching priority populations for CRC screening.
Performance will be measured by the extent to which (1) the program
can demonstrate the appropriate and effective use of public education
and outreach strategies and (2) CRC screening rates are increasing in
both the geographically defined area and the priority population.
4. Quality Assurance/Professional Development
a. Establish standards, systems, policies and procedures to
maintain quality services, including tracking and follow-up systems to
assure the provision of appropriate and timely follow-up of all
abnormal screening results and/or diagnoses of cancer.
b. Change/develop systems or policies to better support high
quality CRC screening and related care based on an assessment and
prioritization of needs.
c. Identify a plan and funding sources to provide treatment for
anyone diagnosed with cancer in the demonstration program.
d. Identify a plan to provide treatment for anyone who incurs an
unanticipated medical complication from services offered within the
demonstration program.
e. Convene a medical advisory board to provide oversight of the
quality of services being delivered throughout the three year funding
period. CDC will be providing medical and clinical technical assistance
to individual programs, and will convene a federal-level CRC
Demonstration Screening Program Workgroup to assist in the development
of overall program policies and procedures.
f. Develop or enhance initiatives to educate and train health
professionals in the detection and control of CRC, including quality of
screening and follow-up care.
Performance will be measured by the extent to which the program (1)
establishes and uses quality indicators, systems and policies/
procedures to monitor and measure the quality of services provided,
including a medical advisory board and; (2) successfully conducts
appropriate and timely follow-up of abnormal test results and provides
referrals to treatment, staging, clinical evaluation of symptoms or
treatment of unanticipated complications.
5. Partnership Development and Maintenance
a. Maintain a relationship with the CDC-funded comprehensive cancer
control (CCC) implementation program(s) (and their coalitions) within
the applicant's state(s) to ensure coordination and integration of
program activities with related CCC activities, including alignment of
program activities with CCC plans.
b. Develop and maintain collaborative partnerships with a diverse
set of entities (such as patients, cancer survivors, community-based
organizations, groups that serve or represent priority populations,
human service agencies, public health agencies, voluntary agencies,
public and private local businesses and employers, nonprofit agencies
and institutions, medical providers and health care system
representatives) to enhance the design and implementation of the
program.
Performance will be measured by the extent to which the program:
(1) Demonstrates a strong association with the CCC program/coalition;
(2) has included any appropriate and diverse additional partners in
program planning; (3) has obtained and can show commitment from
participating partners; (4) has documented the roles that partners and
CCC Coalition members will play; (5) has obtained representation from
the priority populations and has clearly defined a role for
representatives from priority populations in program design and
implementation. A listing of all CDC-funded CCC programs
(implementation level) is provided with this RFA as Attachment A.
6. Data Collection and Tracking
a. Adapt current data collection system and develop data reports to
be submitted to CDC related to CRC screening and other clinical and
program activities that are part of this demonstration project. Please
see Attachment B, Tables B-1 and B-2. These tables represent draft data
items that CDC is proposing should be collected by the grantees to
assess the quality and appropriateness of the services provided within
the demonstration programs. Grantees will be asked to propose data
items they feel would be most effective in showing an increase in
screening in both the geographically-defined population and the
priority population. Grantees will also be asked to propose the best
manner in which to collect these data. Using the information proposed
by grantees and the draft tables in Attachment B, grantees will work
with CDC to finalize an agreed upon set of data items, similar to those
in the draft tables. Grantees must assure that the data collected at
the individual patient-level will be sufficient for grantees to be able
to track the quality and timeliness
[[Page 29750]]
of care (including treatment and routine recall) and will adhere to
current standards related to data-sharing, data security and patient
confidentiality. All submitted data must be de-identified.
Some applicants may only request funds for components of this
program other than screening service delivery. Even if an applicant
chooses to use non-CDC funding sources to fund their screening service
delivery component, all grantees will be required to submit data on the
CRC screening and diagnostic services delivered as part of this
demonstration project.
b. For grantees that request CDC funds for the screening service
delivery component of this program: Collect individual patient-level
data to capture clinical services and outcomes and submit aggregate
data to CDC. Aggregated data reports will include the proportion of
persons within the geographic area defined by the grantee receiving the
specific clinical services offered within this program, by each of the
demographic variables (for example, a report may include the proportion
of persons within the defined geographic area receiving FOBT by age,
gender, race, ethnicity, and income level). Develop data quality
indicators, in conjunction with CDC, to be used by the grantees and CDC
in assessing the quality of the services provided within the
demonstration programs. Grantees may be asked by CDC to submit
individualized data if submitted aggregate data do not meet data
quality indicator standards. The data included in Attachment B, Draft
Table B-1, ``Patient-Related Data Elements,'' variable domains 1-7,
represent the type of information submitted by the program to CDC that
CDC will use to monitor the quality of services delivered (1-unique
identifiers, 2-demographics, 3-screening history, 4-screening
information, 5-diagnostic procedures provided, 6-cancer/polyp
diagnosed, 7-treatment). Final data elements used to obtain this
information will be agreed upon by CDC and the grantees. During the
three year program period, CDC may begin requiring all data submissions
from grantees that receive CDC funds for screening services to be
individual patient-level data, pending approval from the Office of
Management and Budget (OMB).
c. For grantees that do NOT request CDC funds for the screening
service delivery component of this program: collect individual patient-
level data but submit aggregate patient-level data to CDC. Develop data
quality indicators, in conjunction with CDC, to be used by the grantees
and CDC in assessing the quality of the services provided within the
demonstration programs. Submissions will be similar to data received
from grantees described above in (b), but will be aggregate, and not
individual-level. Grantees may be asked by CDC to submit individualized
data if submitted aggregate data do not meet quality indicator
standards.
d. All programs will submit annual program-level data to CDC to be
used to monitor cost and cost-effectiveness, funding sources, program
design and an increase in population-based screening over the three
year program period for the geographically-defined area chosen by the
grantee. The types of data included in Draft Table B-2, ``Program-
Related Data Elements,'' variable domains 1-4, will be required for
submission to CDC (program costs, funding sources, description of
health care delivery systems and population-level screening prevalence
data). Final data elements used to obtain this information will be
agreed upon by CDC and the grantees.
e. The remaining variable domains from both tables are proposed
items that grantees may choose to collect. If programs would like to
collect data items beyond those outlined in Attachment B, they will
need to provide justification.
Performance will be measured based upon: (1) The extent to which
tracking and data collection procedures are in use and form the basis
for quality assurance processes; and (2) the submission of timely and
complete data to CDC.
7. Patient Support
Programs will establish a patient support system to assure that
appropriate screening services are offered, appropriate diagnostic
follow-up is received, appropriate treatment is begun, and that any
appropriate services necessary but not provided by the program are
begun, such as triaging patients with GI symptoms out of the screening
program, to be seen immediately for appropriate diagnostic testing. A
system for the follow-up and referral of a person whose screening test
results are abnormal or suspicious is an essential component of any
comprehensive early detection program. In some instances, diagnostic
testing can be accomplished during the screening test (e.g., if
colonoscopy is used). Clients needing treatment services should be
counseled about their eligibility for public-supported third party
payment and reimbursement programs, if such programs exist. Activities
under patient support should include:
Follow-up of positive screening test results. If any of
the program-selected screening tests other than colonoscopy are
positive, they should be followed by a diagnostic colonoscopy.
Triage of patients to the appropriate health care provider
if they are found to have GI symptoms at program enrollment.
Triage of patients to the appropriate health care provider
if they are found to be at increased risk for CRC at program
enrollment.
Referral of patients for staging or treatment. Programs
must provide appropriate referrals for medical treatment of persons
screened in the program and must ensure, to the extent practicable, the
provision of appropriate follow-up services.
Performance will be measured by the extent to which the program
establishes a system for patient support to assure appropriate follow-
up and referral.
8. Evaluation of the Effectiveness of the Program
Design an evaluation plan to be used to conduct evaluation of
demonstration program activities and improve the quality, effectiveness
and efficiency of program operations.
Performance will be measured by the extent to which programs use
objective, quantitative measures to demonstrate the accomplishment of
program goals, objectives, and intended outcomes and to make program
improvements.
9. Other
Programs may identify other activities that they must pursue in
order to effectively increase CRC screening in their geographically-
defined area and the priority population. Such activities, along with
their justification, must be fully described in the application,
particularly if funding for those activities is being sought.
We anticipate that all funded programs will include the same basic
program activities, although the focus of the activities may differ
slightly across programs. Because applicant needs may differ, not all
programs will require funding for every program activity.
In a cooperative agreement, CDC staff is substantially involved in
the program activities, above and beyond routine grant monitoring.
CDC Activities for this program are as follows:
Provide technical assistance to recipients in the
development, administration, and evaluation of the program efforts to
implement organized community-based CRC screening demonstration
programs.
Assist in the adaptation of existing data collection
strategies and tools to be able to collect data to monitor program
[[Page 29751]]
effectiveness and tracking for this CRC screening demonstration
program. Before screening services are offered under this program, CDC
will evaluate proposed data collection plans.
Evaluate aggregate patient and program-level data received
by the grantees and use the results so that CDC can follow program
activities and provide quality assurance, help grantees strengthen
their programs, make mid-course corrections and document successes. For
grantees who only submit aggregate patient-level data (those who do NOT
receive CDC funds for screening), if submitted aggregate patient-level
data do not meet quality indicator standards, CDC may request
individualized data and will work with the grantee to resolve data
questions.
Review and assist with refining the evaluation plan
designed/proposed by the grantee to make sure it will be adequate to
monitor the goals and objectives of this program. Work closely with
grantees throughout the three year funding period to assist programs
with evaluation of their demonstration programs and to assure adequate
documentation of successes and sharing of applicable strategies and
tools across programs.
Work with grantees to finalize a set of data quality
indicators to be used by the grantees and CDC in assessing the quality
of the services provided within the demonstration programs.
Within the first six months, advise on the design of a
data collection approach, to make sure that the proposed approach is
reasonably certain to achieve the goals of this program. Determine with
the funded program that screening services and data collection are
ready to begin.
Provide patient and health care provider education
materials from CDC's Screen for Life: National Colorectal Cancer Action
Campaign, such as brochures, fact sheets, medical office displays, etc.
which can be adapted as necessary.
Regularly review the literature to ensure that grantees
are being provided technical assistance and consultation that reflects
the most up-to-date science and practice.
Convene a CRC Demonstration Screening Program Workgroup,
to help oversee program activities and address clinical and other
issues.
Convene a meeting of the funded programs for information
sharing, problem solving, and training at least annually.
Conduct a site visit within the first six months of award
to assure program readiness, and subsequently, to assess program
progress and mutually resolve problems, as needed.
Assess program readiness by addressing the following
issues: (1) The identification of providers to perform screening and
follow-up service, and to provide care in the event of unanticipated
complications; (2) a final data collection and tracking system; (3) a
plan and funding sources to provide treatment for those persons in whom
cancers are identified; (4) a plan for the use of quality indicators to
evaluate the appropriate use of clinical services and (5) a plan for
recruiting individuals for screening in their geographically-defined
area and the priority population.
II. Award Information
Type of Award: Cooperative Agreement. CDC involvement in this
program is listed in the Activities Section above.
Fiscal Year Funds: 2005.
Approximate Total Funding: $2,000,000.
Approximate Number of Awards: Three to Five.
Approximate Average Award: $600,000. (This amount is for the first
12-month budget period, and includes both direct and indirect costs.)
Floor of Award Range: None.
Ceiling of Award Range: None.
Anticipated Award Date: August, 2005.
Budget Period Length: 12 months.
Project Period Length: Three years.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal Government.
III. Eligibility Information
III.1. Eligible Applicants
To be eligible, applicants must demonstrate a relationship with a
CDC funded CCC program (implementation level) within their state(s).
Applicants will need to clearly define the geographic area covered by
their proposed program.
Applications may be submitted by public and private nonprofit
organizations and by governments and their agencies, such as:
Public nonprofit organizations
Private nonprofit organizations
Universities
Colleges
Research institutions
Hospitals
Community-based organizations
Cancer Centers
Community Health Centers
Regional Hospital Systems
Large Physician Group Practices
Health Maintenance Organizations
Large Public Employers, that do not provide coverage for
cancer screenings
Defined Metropolitan Areas
Rural health organizations/consortia
Multi-federal agency consortium covering a defined
geographic area
Other large defined health care systems
Federally recognized Indian tribal governments
Indian tribes
Indian tribal organizations
State and local governments or their Bona Fide Agents
(this includes the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, the Commonwealth of the Northern Marianna
Islands, American Samoa, Guam, the Federated States of Micronesia, the
Republic of the Marshall Islands, and the Republic of Palau)
Political subdivisions of States (in consultation with
States)
A Bona Fide Agent is an agency/organization identified by the state
as eligible to submit an application under the state eligibility in
lieu of a state application. If you are applying as a bona fide agent
of a state or local government, you must provide a letter from the
state or local government as documentation of your status. Place this
documentation behind the first page of your application form.
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
III.3. Other
Special Requirements
If your application is incomplete or non-responsive to the special
requirements listed in this section, it will not be entered into the
review process. You will be notified that your application did not meet
submission requirements.
Late applications will be considered non-responsive. See
section ``IV.3. Submission Dates and Times'' for more information on
deadlines.
To be eligible, applicants must demonstrate a relationship
with a CDC-funded CCC program (implementation level) within their
state(s) by providing a letter of support (in the application
appendices) from the CDC funded CCC program (implementation level)
indicating support for the CRC
[[Page 29752]]
demonstration screening program. Applications that do not contain a
letter of support from the CDC funded CCC program (implementation
level) will not be considered for review. More than one application can
be submitted per state, but only one application per state will be
selected by CDC. Applicants will need to clearly define the geographic
area that their program will cover.
Note: Title 2 of the United States Code Section 1611 states that
an organization described in Section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.
IV. Application and Submission Information
IV.1. Address To Request Application Package
To apply for this funding opportunity use application form PHS
5161-1.
CDC strongly encourages you to submit your application
electronically by utilizing the forms and instructions posted for this
announcement at https://www.grants.gov.
Application forms and instructions are available on the CDC Web
site, at the following Internet address: https://www.cdc.gov/od/pgo/
forminfo.htm.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Submission
Letter of Intent (LOI): Your LOI must be written in the following
format:
Maximum number of pages: Two
Font size: 12-point unreduced
Single spaced
Paper size: 8.5 by 11 inches
Page margin size: One inch
Printed only on one side of page
Written in plain language, avoid jargon
Your LOI must contain the following information:
Program title and number listed in this RFA
Type of organization submitting the application
Name of the organization submitting the application
Amount of funding request
Official contact person's name, telephone number, fax
number, mailing address and e-mail address
Application: You must submit a project narrative with your
application forms. The narrative must be submitted in the following
format:
Maximum number of pages: 30. If your narrative exceeds the
page limit, only the first pages which are within the page limit will
be reviewed.
Font size: 12 point unreduced
Double spaced
Paper size: 8.5 by 11 inches
Page margin size: One inch
Printed only on one side of page
Held together only by rubber bands or metal clips; not
bound in any other way.
All activities designed to reach the objectives of the RFA need to
be described. Even if an applicant determines that one or several pre-
existing program activities do not require CDC resources, a description
of those activities must be included in the application, and those
elements will be evaluated.
Your narrative should address activities to be conducted over the
entire project period, and must include the following items in the
order listed:
Executive Summary
Applicants should provide a clear, concise one to two page summary
to include:
Description of the community where the program will take
place, including the geographic boundaries.
A short description of existing or proposed CRC screening
program, including priority population to be screened.
Amount of funding requested.
Background and Need
Describe the need for this program within the proposed
geographically-defined population and among the priority population.
The following information should be included:
Description and size of larger geographically-defined
population and the priority population for the program (if a different
priority population is chosen from what is defined in this RFA, the
applicant must provide a justification for choosing that priority
population).
Description of the burden of CRC within the community/
population.
Proportion of the priority population currently screened.
Existing and Proposed Program Description (including Capacity)
Describe the existing and/or proposed program in detail including:
All program components, including those outlined in the
``Activities'' section of this RFA and any additional activity proposed
by the applicant.
Which program activities are already existing (if any) and
which will/will not be supported by CDC funding.
Methods for data collection designed to show an increase
in screening in both the geographically defined population and the
priority population. Include a list of proposed data elements, a
proposed plan to gather those data, and plans for assuring data
security, protecting patient confidentiality and de-identifying data.
Which screening and diagnostic tests will be used and the
rationale for the selection of screening and diagnostic tests.
The number of new clients expected to be screened.
A description of how the priority population will be
reached.
Overall capability of providing the program, including the
applicant's history and experience with proposed activities and
services related to providing colorectal screening.
The capacity to offer these tests to the intended
audience, including the identification of providers and a follow-up/
referral plan.
Program Management
Describe the organization's structure and function, size,
activities and methods of routine communication with staff. Describe
each current or proposed staff position for this initiative by job
title, function, education and experience, general duties, and
activities with which that position will be involved. Describe a
proposed fiscal system to track and monitor program expenditures and to
ensure the accurate and timely reimbursement of services provided by
the program.
Workplan
The applicant should provide a detailed work plan for the first
year that describes how the proposed activities will be conducted. The
work plan should include the following:
Objectives: Specific, realistic, time-phased and
measurable short-term (one year) and long-term (three year) objectives
consistent with the intent of this program announcement, including
targets for screening. The first six months will be for start up, to
include finalizing the data collection system with CDC, finalizing the
evaluation plan with CDC, and implementing all start up activities so
that service delivery may begin within six months of award.
Activities: Specific activities and strategies that will
be undertaken to achieve each of the proposed short-term objectives
during the budget period.
Time Line: A time line for assessing progress in meeting
objectives.
Staff Responsibility: Staff responsible for completion of
activities.
[[Page 29753]]
Measures of Effectiveness: How activities and their impact
will be evaluated, including indicators of program success.
Data: A list of sources that will be used to gather
information on measures of effectiveness.
Grantees may choose to use the attached work plan format to present
this information (See Attachment C of this RFA).
Collaborative Activities
Describe existing or proposed partnership to support the program,
including linkages with the appropriate CCC implementation program(s)
and coalition partners. Describe a process for maintaining a
relationship with the CCC program/coalition and ensuring that program
activities are aligned with CCC plan strategies related to CRC. Provide
a letter of support from the CCC Coalition that: (1) Verifies that the
applicant's proposal aligns with CRC priorities as defined in the
Cancer Plan; and (2) describes methods by which Coalition or individual
members will be engaged in the demonstration CRC screening program.
Evaluation
The applicant should describe existing or proposed evaluation
activities. Using this outline and CDC's draft evaluation plan, the
applicant will work with CDC to finalize an evaluation plan to be
completed within the first six months of award. This evaluation plan
will be used by the program with CDC to evaluate each program goal and
objective and to use the evaluation results to improve program
effectiveness. Describe who will be responsible for conducting
evaluation activities and working with CDC on a formal evaluation of
the program.
Budget and Justification (Narrative Justification Will Not Be Counted
Toward Application Page Limit)
Provide a detailed line item budget and narrative justification of
all operating expenses consistent with the proposed objectives and
planned activities. Each budget item should be clearly related to a
stated activity.
Participation in CDC sponsored training, workshops, or meetings is
essential to the effective implementation of this program. Travel funds
should be budgeted for the following meetings:
One to two persons to Atlanta, Georgia to discuss program
implementation progress (reverse site visit) and for consultation and
technical assistance (two days, one trip per year.)
Up to two additional two-person trips to Atlanta, or other
destinations to attend or assist with national workgroups, task forces,
or committees (one to three days.)
Additional information may be included in the application
appendices. The appendices will not be counted toward the narrative
page limit. This additional information includes:
Curriculum vitae.
Job descriptions.
Organizational charts.
Letters of support.
Any other supporting documentation.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. The DUNS number is a nine-digit
identification number, which uniquely identifies business entities.
Obtaining a DUNS number is easy and there is no charge. To obtain a
DUNS number, access https://www.dunandbradstreet.com or call 1-866-705-
5711. For more information, see the CDC Web site at: https://
www.cdc.gov/od/pgo/funding/pubcommt.htm.
If your application form does not have a DUNS number field, please
write your DUNS number at the top of the first page of your
application, and/or include your DUNS number in your application cover
letter.
Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
LOI Deadline Date: June 8, 2005.
CDC requests that you send a LOI if you intend to apply for this
program. Although the LOI is not required, is not binding, and does not
enter into the review of your subsequent application, the LOI will be
used to gauge the level of interest in this program, and to allow CDC
to plan the application review.
Application Deadline Date: July 8, 2005.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. Eastern Time on the deadline
date.
You may submit your application electronically at https://
www.grants.gov. Applications completed online through Grants.gov are
considered formally submitted when the applicant organization's
Authorizing Official electronically submits the application to
www.grants.gov. Electronic applications will be considered as having
met the deadline if the application has been submitted electronically
by the applicant organization's Authorizing Official to Grants.gov on
or before the deadline date and time.
If you submit your application electronically with Grants.gov, your
application will be electronically time/date stamped, which will serve
as receipt of submission. You will receive an e-mail notice of receipt
when CDC receives the application.
If you submit your application by the United States Postal Service
or commercial delivery service, you must ensure that the carrier will
be able to guarantee delivery by the closing date and time. If CDC
receives your submission after closing due to: (1) Carrier error, when
the carrier accepted the package with a guarantee for delivery by the
closing date and time, or (2) significant weather delays or natural
disasters, you will be given the opportunity to submit documentation of
the carriers guarantee. If the documentation verifies a carrier
problem, CDC will consider the submission as having been received by
the deadline.
If you submit a hard copy of your application, CDC will not notify
you upon receipt of your submission. If you have a question about the
receipt of your LOI or application, first contact your courier. If you
still have a question, contact the PGO-TIM staff at: 770-488-2700.
Before calling, please wait two to three days after the submission
deadline. This will allow time for submissions to be processed and
logged.
This announcement is the definitive guide on LOI and application
content, submission address, and deadline. It supersedes information
provided in the application instructions. If your submission does not
meet the deadline above, it will not be eligible for review, and will
be discarded. You will be notified that you did not meet the submission
requirements.
IV.4. Intergovernmental Review of Applications
Executive Order 12372 does not apply to this program.
IV.5. Funding restrictions
Restrictions, which must be taken into account while writing your
budget, are as follows:
Funds may not be used for research.
Reimbursement of pre-award costs is not allowed.
Funds may not be used for the purchase or lease of land or
buildings, construction of facilities, renovation of existing space.
Funds may not be used for the endorsement or promotion of
any drugs,
[[Page 29754]]
health products, or medical supplies and equipment.
Funds may be used to support personnel and to purchase
supplies and services directly related to program activities consistent
with the scope of this announcement. While the purchase of equipment is
discouraged, it will be considered for approval if justified on the
basis of being essential to the program and not available from another
source.
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement should be less than 12
months of age.
Guidance for completing your budget can be found on the CDC Web
site, at the following Internet address: https://www.cdc.gov/od/pgo/
funding/budgetguide.htm.
IV.6. Other Submission Requirements
LOI Submission Address: Submit your LOI by express mail, delivery
service, fax, or E-mail to: Tanya Hicks, Centers for Disease Control
and Prevention, National Center for Chronic Disease Prevention and
Health Promotion, 4770 Buford Highway, MS K-57, Atlanta, Georgia 30341.
Telephone: (770) 488-4325. Fax: (770) 488-3230. E-mail: THicks@cdc.gov.
Application Submission Address: CDC strongly encourages applicants
to submit electronically at: https://www.grants.gov. You will be able to
download a copy of the application package from https://www.grants.gov,
complete it offline, and then upload and submit the application via the
Grants.gov site. E-mail submissions will not be accepted. If you are
having technical difficulties in Grants.gov, they can be reached by e-
mail at support@grants.gov or by phone at 1-800-518-4726 (1-800-518-
GRANTS). The Customer Support Center is open from 7 a.m. to 9 p.m.
Eastern Time, Monday through Friday.
CDC recommends that you submit your application to Grants.gov early
enough to resolve any unanticipated difficulties prior to the deadline.
You may also submit a back-up paper submission of your application. Any
such paper submission must be received in accordance with the
requirements for timely submission detailed in Section IV.3. of the
grant announcement. The paper submission must be clearly marked:
``BACK-UP FOR ELECTRONIC SUBMISSION.''
The paper submission must conform to all requirements for non-
electronic submissions. If both electronic and back-up paper
submissions are received by the deadline, the electronic version will
be considered the official submission.
It is strongly recommended that you submit your grant application
using Microsoft Office products (e.g., Microsoft Word, Microsoft Excel,
etc.). If you do not have access to Microsoft Office products, you may
submit a PDF file. Directions for creating PDF files can be found on
the Grants.gov Web site. Use of file formats other than Microsoft
Office or PDF may result in your file being unreadable by our staff;
Or
Submit the original and two hard copies of your application by mail
or express delivery service to: Technical Information Management-RFA
AA030, CDC Procurement and Grants Office, 2920 Brandywine Road,
Atlanta, GA 30341.
V. Application Review Information
V.1. Criteria
Applicants are required to provide measures of effectiveness that
will demonstrate the accomplishment of the various identified
objectives of the cooperative agreement. Measures of effectiveness must
relate to the performance goals stated in the ``Purpose'' section of
this announcement. Measures must be objective and quantitative, and
must measure the intended outcome. These measures of effectiveness must
be submitted with the application and will be an element of evaluation.
Your application will be evaluated against the following criteria:
Existing and Proposed Program Description (Including Capacity) (30
Points)
(a) Overall preparedness (5 points): Does the applicant describe
its capability to carry out the proposed objectives of this program,
including demonstrating past success with similar programs?
(b) Reaching population to be served (5 points): Does the applicant
propose a projected number of screens or a proportional target increase
in screening? Does the applicant outline a plan to reach and recruit
both the larger population in the geographically defined area and the
priority population?
(c) Description of program components (10 points): Does the
applicant include a description of all program components (including
data collection and tracking, quality assurance and professional
development, case management, public education and outreach, and other
proposed activities) and indicate which will/will not be supported by
CDC funding? Are methods for data collection designed to show an
increase in screening in both the geographically defined population and
the priority population described? Are a list of proposed data
elements, a proposed plan to gather those data elements, and plans for
assuring data security, protecting patient confidentiality and de-
identifying data included?
(d) Description of tests to be used within demonstration program (5
points): Are the screening and diagnostic tests selected adequately
described, including a rationale for selection? Are the proposed tests
consistent with USPSTF guidelines? Does the applicant describe adequate
availability of selected tests and demonstrate the capacity to offer
these tests?
(e) Treatment and complications (5 points): Has the applicant
addressed how clients will be offered treatment if a cancer is
detected, and how complications will be managed?
Work Plan (20 Points)
(a) Appropriate objectives (10 points): Are proposed short-term
(one year) and long-term (three year) objectives specific, time-phased,
measurable, realistic, related to identified needs and consistent with
the purpose of this program announcement?
(b) Appropriate strategies (10 points): Does the applicant's plan
for achieving the proposed activities appear realistic and feasible and
relate to the programmatic requirements and purposes of this program
announcement?
Collaborative Activities (20 Points)
(a) Linkage with CCC (10 points): Is a linkage established with a
CDC-funded CCC implementation program(s) and coalition? Does the
applicant provide a letter of support from the CCC program/coalition
providing details of its relationship to the applicant and commitment
to ensuring linkages to CCC plan implementation?
(b) Working with diverse partners (10 points): Does the applicant
describe clear and complete plans to develop or maintain active working
relationships with other organizations, agencies, or partners in the
design and implementation of the program?
Evaluation (10 Points)
Do the proposed evaluation activities address progress toward
meeting goals and objectives, describe indicators of program success,
and appear to be reasonable and feasible? Does the
[[Page 29755]]
applicant describe how evaluation results will be used to improve
program effectiveness? Do they describe who will be responsible for
evaluation activities?
Program Management (10 Points)
Does the applicant describe the organization's size, structure and
function? Does the applicant demonstrate ability to manage the project,
including clear lines of communication and organizational support? Is
each current or proposed staff position for this initiative described
(including job title, function, required education and experience,
general duties, and activities with which that position will be
involved)? Does the applicant describe a proposed fiscal system to
track and monitor program expenditures and to ensure the accurate and
timely reimbursement of services provided by the program?
Background and Need (10 Points)
For applicants addressing population-based CRC screening among
persons 50 years and older in a geographically defined area, and
focusing screening efforts on persons 50 years and older with low
incomes and inadequate or no health insurance coverage for CRC
screening (priority population):
Does the applicant adequately describe the need for this program?
Does the applicant define the geographic area that their program will
cover? Are the characteristics and the size of the defined priority
population described? Is the burden of cancer among the community and
the priority population described? Is the current CRC screening test
prevalence of persons in the defined geographic area and the priority
population described?
Or,
For applicants addressing population-based CRC screening among
persons 50 years and older in a geographically defined area, and
focusing screening efforts on a priority population other than persons
50 years and older with low incomes and inadequate or no health
insurance coverage for CRC screening:
Does the applicant adequately describe the need for this program?
Does the applicant define the geographic area that their program will
cover? Are the characteristics and the size of the defined priority
population described? Does the applicant provide a justification for
selecting a priority population different from the priority population
defined in this RFA? Is the burden of cancer among the community and
the priority population described? Is the current CRC screening test
prevalence of persons in the defined geographic area and the priority
population described?
Executive Summary (Not Scored)
Does the applicant provide an executive summary that describes the
community the program will cover, a short description of the proposed
program and the amount of funding requested?
Budget and Justification (Not Scored)
Is the budget well defined, reasonable, and consistent with the
purpose of the program and the activities proposed? Is a narrative
justification provided? Are required travel funds requested?
V.2. Review and Selection Process
Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO) staff and for responsiveness by the Division of
Cancer Prevention and Control. Incomplete applications and applications
that are non-responsive to the eligibility criteria will not advance
through the review process. Applicants will be notified that their
application did not meet submission requirements.
An objective review panel will evaluate complete and responsive
applications according to the criteria listed in the ``V.1. Criteria''
section above. Applications will be funded in order by score and rank
determined by the review panel.
V.3. Anticipated Announcement and Award Dates
Anticipated date of award is August 31, 2005.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Award (NoA) from the
CDC Procurement and Grants Office. The NoA shall be the only binding,
authorizing document between the recipient and CDC. The NoA will be
signed by an authorized Grants Management Officer, and mailed to the
recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements
45 CFR Part 74 and Part 92
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: https://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
AR-8 Public Health System Reporting Requirements.
AR-9 Paperwork Reduction Act Requirements.
AR-10 Smoke-Free Workplace Requirements.
AR-11 Healthy People 2010.
AR-12 Lobbying Restrictions.
AR-14 Accounting System Requirements.
AR-15 Proof of Non-Profit Status.
AR-24 Health Insurance Portability and Accountability Act
Requirements.
AR-25 Release and Sharing of Data.
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: https://www.cdc.gov/od/
pgo/funding/ARs.htm.
An additional Certifications form from the PHS 5161-1 application
needs to be included in your Grants.gov electronic submission only.
Refer to https://www.cdc.gov/od/pgo/funding/PHS5161-1Certificates.pdf.
Once the form is filled out, attach it to your Grants.gov submission as
Other Attachment Forms.
VI.3. Reporting Requirements
You must provide CDC with an original, plus two hard copies of the
following reports:
1. Interim progress report, due no less than 90 days before the end
of the budget period. The progress report will serve as your non-
competing continuation application, and must contain the following
elements:
a. Current Budget Period Activities Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activity Objectives.
d. Budget for new budget period.
e. Measures of Effectiveness.
f. Additional Requested Information.
2. Financial status report and annual progress report, no more than
90 days after the end of the budget period.
3. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be mailed to the Grants Management or Contract
Specialist listed in the ``Agency Contacts'' section of this
announcement.
Additional Reporting Requirements
Patient-related and program-related data (as defined in the
``Activities,'' ``Data Collection and Tracking'' section of this RFA)
is due to CDC on a routine basis.
[[Page 29756]]
All programs will submit program-related data annually
(June 1).
Programs receiving CDC funds for screening services will
submit aggregate patient-related data quarterly (March 1, June 1,
October 1 and December 1), but be required to switch to submission of
individual patient-related data during the 3 year program period,
pending approval from OMB.
Programs NOT receiving CDC funds for screening services
will submit aggregate patient-related data quarterly (March 1, June 1,
October 1 and December 1).
In year 01 of the program, the first patient-level data
will be due March 1, 2006 and first program-related data will be due
June 1, 2006.
VII. Agency Contacts
We encourage inquiries concerning this announcement. For general
questions, contact: Technical Information Management Section, CDC
Procurement and Grants Office, 2920 Brandywine Road. Atlanta, GA 30341.
Telephone: 770-488-2700.
For program technical assistance, Laura Seeff, MD, Centers for
Disease Control and Prevention, National Center for Chronic Disease
Prevention and Health Promotion, 4770 Buford Highway, MS K-55, Atlanta,
Georgia 30341. 770-488-3223. E-mail address: lseeff@cdc.gov;
Or
Leslie Given, MPA, Centers for Disease Control and Prevention,
National Center for Chronic Disease Prevention and Health Promotion,
4770 Buford Highway, MS K-57, Atlanta, Georgia 30341. Telephone: (770)
488-3099. E-mail address: lgiven@cdc.gov.
For financial, grants management, or budget assistance, contact:
Barbara Rene Benyard, Grants Management Specialist, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341. Telephone: 770/
488-2757. E-mail: bnb8@cdc.gov.
VIII. Other Information
This and other CDC funding opportunity announcements can be found
on the CDC Web site, Internet address: https://www.cdc.gov. Click on
``Funding'' then ``Grants and Cooperative Agreements.'' Additional
information about CRC can be found at the CDC Division of Cancer
Prevention and Control Web site https://www.cdc.gov/cancer/colorctl/
index.htm.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention.
Attachment A--CDC National Comprehensive Cancer Control Program
Implementation Programs (as of March 1, 2005)
Alabama
Arkansas
California
Colorado
Florida
Georgia
Hawaii
Iowa
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Missouri
Nebraska
New Jersey
New Mexico
New York
North Carolina
Northwest Portland Area Indian Health Board
Ohio
Pennsylvania
Rhode Island
Texas
Utah
Virginia
Washington
West Virginia
Attachment B
Table B-1.--DRAFT Patient-Related Data Elements
------------------------------------------------------------------------
Samples of potential
Variable domains Possible data use of data elements
elements for evaluation
------------------------------------------------------------------------
1. Unique Identifiers....... Patient
identifier.
Record
identifier.
2. Demographics............. Date of Proportion
birth. of individuals
screened within the
specified program
catchment area.
Gender.
Race/
ethnicity
(collected as
separate fields)..
County of
residence, state,
zip code..
3. Screening History........ Previous Proportion
CRC test (FOBT, of rarely/never
FIT, colonoscopy screened
etc.). participants.
Date
performed (month,
year for each)
Results for
each (most recent
result for each
test).
4. Screening Information.... Date and Types of
type of procedure providers
provided. performing
enrollment and